#  @BioTechHealthX BioTech Health X BioTech Health X posts on X about health, nasdaq, stocks, strong the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::1387526045134462978/interactions)  - [--] Week [-----] +181% - [--] Month [-----] -4.80% - [--] Months [------] +224% - [--] Year [------] +6,857% ### Mentions: [--] [#](/creator/twitter::1387526045134462978/posts_active)  - [--] Month [--] -52% - [--] Months [---] +390% - [--] Year [---] +8,775% ### Followers: [---] [#](/creator/twitter::1387526045134462978/followers)  - [--] Week [---] +2.50% - [--] Month [---] +3.80% - [--] Months [---] +23% - [--] Year [---] +46% ### CreatorRank: [---------] [#](/creator/twitter::1387526045134462978/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [exchanges](/list/exchanges) [cryptocurrencies](/list/cryptocurrencies) [countries](/list/countries) [technology brands](/list/technology-brands) [automotive brands](/list/automotive-brands) [currencies](/list/currencies) [travel destinations](/list/travel-destinations) [champions league](/list/champions-league) **Social topic influence** [health](/topic/health), [nasdaq](/topic/nasdaq) #741, [stocks](/topic/stocks), [strong](/topic/strong), [wall street](/topic/wall-street), [target](/topic/target), [future](/topic/future), [longterm](/topic/longterm), [breakout](/topic/breakout), [market cap](/topic/market-cap) #941 **Top accounts mentioned or mentioned by** [@jnjnews](/creator/undefined) [@novonordisk](/creator/undefined) [@unitedhealthgrp](/creator/undefined) [@4dmolecular](/creator/undefined) [@transmedics](/creator/undefined) [@crinetics](/creator/undefined) [@sellaslife](/creator/undefined) [@oscarhealth](/creator/undefined) [@pfizer](/creator/undefined) [@novavax](/creator/undefined) [@immunitybio](/creator/undefined) [@tgtherapeutics](/creator/undefined) [@axsome](/creator/undefined) [@brightmindsbio](/creator/undefined) [@elilillyandco](/creator/undefined) [@axogen](/creator/undefined) [@krystalbiotech](/creator/undefined) [@urogenpharma](/creator/undefined) [@teamnovonordisk](/creator/undefined) [@admabiologics](/creator/undefined) **Top assets mentioned** [Novo-Nordisk (NVO)](/topic/$nvo) [Johnson & Johnson (JNJ)](/topic/$jnj) [UnitedHealth Group (UNH)](/topic/$unh) [Candel Therapeutics, Inc. (CADL)](/topic/$cadl) [Molina Healthcare, Inc. (MOH)](/topic/$moh) [Cadrenal Therapeutics, Inc. (CVKD)](/topic/$cvkd) [Intuitive Surgical, Inc. (ISRG)](/topic/$isrg) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [4D Molecular Therapeutics Inc. (FDMT)](/topic/$fdmt) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [TransMedics Group, Inc. Common Stock (TMDX)](/topic/$tmdx) [Crinetics Pharmaceuticals, Inc. (CRNX)](/topic/$crnx) [Boston Scientific Corporation (BSX)](/topic/boston-scientific) [Basilisk (BSX)](/topic/$bsx) [Oscar Health, Inc. (OSCR)](/topic/$oscr) [Novavax Inc (NVAX)](/topic/$nvax) [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Elevance Health Inc (ELV)](/topic/$elv) [Kyverna Therapeutics, Inc. (KYTX)](/topic/$kytx) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Greenwich LifeSciences, Inc. (GLSI)](/topic/$glsi) [Prelude Therapeutics Inc. (PRLD)](/topic/$prld) [Janux Therapeutics, Inc. (JANX)](/topic/$janx) [BEAM (BEAM)](/topic/$beam) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Eli Lilly and Company (LLY)](/topic/$lly) [Krystal Biotech, Inc. Common Stock (KRYS)](/topic/$krys) [ADMA Biologics, Inc. (ADMA)](/topic/$adma) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Emergent Biosolutions, Inc. (EBS)](/topic/$ebs) [Metsera, Inc. (MTSR)](/topic/$mtsr) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) ### Top Social Posts Top posts by engagements in the last [--] hours "Biotech Stocks Soaring Today $JANX 187% $VJTX 63% $HIMS 29% $BEAM 33% $OAC 30% $AHCO 30%" [X Link](https://x.com/BioTechHealthX/status/1762503308676055171) 2024-02-27T15:41Z [---] followers, [---] engagements ".@EliLillyandCo announced at the #INGlobalSummit w/ @GovHolcomb a $5.3B investment into the company's Lebanon Indiana production facility set to meet the increasing demand for its diabetes and weight loss drugs Mounjaro and Zepbound. $LLY https://biotechhealthx.com/biotech-news/eli-lilly-announces-historic-5-3-billion-investment-to-expand-indiana-manufacturing-for-diabetes-and-weight-loss-drugs/ https://biotechhealthx.com/biotech-news/eli-lilly-announces-historic-5-3-billion-investment-to-expand-indiana-manufacturing-for-diabetes-and-weight-loss-drugs/" [X Link](https://x.com/BioTechHealthX/status/1794056131150487930) 2024-05-24T17:21Z [---] followers, [--] engagements "New @NovoNordiskUS Phase [--] FLOW study published in @NEJM highlights Ozempic's significant benefits in reducing risk of kidney disease events cardiovascular issues & mortality in patients with type [--] diabetes and chronic kidney disease. $NVO https://biotechhealthx.com/biotech-news/ozempic-shows-lower-risk-of-kidney-and-heart-complications-in-diabetic-patients/ https://biotechhealthx.com/biotech-news/ozempic-shows-lower-risk-of-kidney-and-heart-complications-in-diabetic-patients/" [X Link](https://x.com/BioTechHealthX/status/1794071157613678755) 2024-05-24T18:21Z [---] followers, [---] engagements "$TBPH This cash-rich debt-free company is advancing a rare disease blockbuster while pulling in strong COPD revenue. Check Theravance Biopharma. https://biotechhealthx.com/biotech-news/biotech-bargain-alert-theravance-biopharma-tbph-may-offer-triple-digit-upside-in-2025/ https://biotechhealthx.com/biotech-news/biotech-bargain-alert-theravance-biopharma-tbph-may-offer-triple-digit-upside-in-2025/" [X Link](https://x.com/BioTechHealthX/status/1941193635833446456) 2025-07-04T17:53Z [---] followers, [--] engagements "$PTHS @PelthosT just closed a strategic merger & is launching its first drug. With a clean balance sheet and big vision investors are taking notice. https://biotechhealthx.com/biotech-news/pelthos-therapeutics-pths-zero-debt-50m-in-cash-and-an-fda-greenlight-whats-not-to-love/ https://biotechhealthx.com/biotech-news/pelthos-therapeutics-pths-zero-debt-50m-in-cash-and-an-fda-greenlight-whats-not-to-love/" [X Link](https://x.com/BioTechHealthX/status/1941193818168324534) 2025-07-04T17:54Z [---] followers, [--] engagements "$GSK After spinning off Haleon & supercharging its pipeline GlaxoSmithKline has outpaced the medical sector by 16% YTD. Analysts are bullish. https://biotechhealthx.com/biotech-news/glaxosmithkline-gsks-reinvention-is-complete-will-this-drug-giant-deliver-50-upside-in-2025/ https://biotechhealthx.com/biotech-news/glaxosmithkline-gsks-reinvention-is-complete-will-this-drug-giant-deliver-50-upside-in-2025/" [X Link](https://x.com/BioTechHealthX/status/1941194282876142044) 2025-07-04T17:55Z [---] followers, [--] engagements "$AIM Backed by a fresh patent stock split & NYSE compliance extension AIM Immunotech is ready to rebound hard in [----]. See why this stock is a smart pick https://biotechhealthx.com/biotech-news/from-penny-stock-to-powerhouse-aim-immunotech-aims-comeback-could-be-epic/ https://biotechhealthx.com/biotech-news/from-penny-stock-to-powerhouse-aim-immunotech-aims-comeback-could-be-epic/" [X Link](https://x.com/BioTechHealthX/status/1941332818854048119) 2025-07-05T03:06Z [---] followers, [--] engagements "$AMGN A deep pipeline blockbuster drugs & $27B acquisitions @Amgen is set to dominate in obesity oncology & rare diseases. Dont miss the chance https://biotechhealthx.com/biotech-news/buy-the-biotech-blue-chip-before-the-surge-why-amgen-amgn-could-soar-in-2025/ https://biotechhealthx.com/biotech-news/buy-the-biotech-blue-chip-before-the-surge-why-amgen-amgn-could-soar-in-2025/" [X Link](https://x.com/BioTechHealthX/status/1941898835091128494) 2025-07-06T16:35Z [---] followers, [--] engagements "$MOH Molina Healthcare's shares skidded to $262 even after crushing Q1 earnings. See why investors are calling this the best bargain in healthcare. https://biotechhealthx.com/biotech-news/buy-the-dip-molina-healthcare-moh-just-hit-a-52-week-low-and-the-upside-is-stunning/ https://biotechhealthx.com/biotech-news/buy-the-dip-molina-healthcare-moh-just-hit-a-52-week-low-and-the-upside-is-stunning/" [X Link](https://x.com/BioTechHealthX/status/1941899009649692681) 2025-07-06T16:36Z [---] followers, [--] engagements "$JNJ Stable cash-rich and innovation-focused @JNJ checks all the boxesso why isnt it in Buffetts portfolio And should it be in yours https://biotechhealthx.com/biotech-news/warren-buffett-missed-this-one-why-johnson-johnson-jnj-may-be-the-best-buy-he-never-made/ https://biotechhealthx.com/biotech-news/warren-buffett-missed-this-one-why-johnson-johnson-jnj-may-be-the-best-buy-he-never-made/" [X Link](https://x.com/BioTechHealthX/status/1941899332023996619) 2025-07-06T16:37Z [---] followers, [--] engagements "$ABEO After cutting losses & scoring a huge gene therapy approval @AbeonaBio is seen to be profitable in [----]. See why Wall Street is turning bullish. https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-s-set-to-breakeven-and-analysts-say-its-just-the-beginning/ https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-s-set-to-breakeven-and-analysts-say-its-just-the-beginning/" [X Link](https://x.com/BioTechHealthX/status/1946414302631711159) 2025-07-19T03:38Z [---] followers, [--] engagements "$AXGN With global expansion FDA approvals & high-margin growth @axogen is rewriting the rules of nerve regeneration. Check this out. https://biotechhealthx.com/biotech-news/axogen-axgn-is-reinventing-nerve-repair-and-it-could-make-early-investors-rich/ https://biotechhealthx.com/biotech-news/axogen-axgn-is-reinventing-nerve-repair-and-it-could-make-early-investors-rich/" [X Link](https://x.com/BioTechHealthX/status/1946414659600576767) 2025-07-19T03:39Z [---] followers, [---] engagements "$HNST The Honest Company is turning heads with [--] straight quarters of positive EBITDA zero debt and explosive retail expansion potential. https://biotechhealthx.com/biotech-news/the-honest-company-hnst-could-be-wall-streets-most-underrated-clean-brand-stock-right-now/ https://biotechhealthx.com/biotech-news/the-honest-company-hnst-could-be-wall-streets-most-underrated-clean-brand-stock-right-now/" [X Link](https://x.com/BioTechHealthX/status/1946979760313344163) 2025-07-20T17:05Z [---] followers, [---] engagements "$REPL Analysts are piling on @Replimune with bullish price targets ahead of RP1s FDA decision. See why REPL could surge in [----]. https://biotechhealthx.com/biotech-news/wall-street-sees-75-upside-is-replimune-repl-the-best-biotech-stock-to-buy-now/ https://biotechhealthx.com/biotech-news/wall-street-sees-75-upside-is-replimune-repl-the-best-biotech-stock-to-buy-now/" [X Link](https://x.com/BioTechHealthX/status/1947251832335614461) 2025-07-21T11:06Z [---] followers, [----] engagements "$TMDX Just like @Tesla reimagined vehicles @Transmedics is redefining organ transport. See how TMDXs OCS platform is turning heads on Wall Street. https://biotechhealthx.com/biotech-news/transmedics-tmdx-could-be-the-tesla-of-transplants-heres-why-investors-are-paying-attention/ https://biotechhealthx.com/biotech-news/transmedics-tmdx-could-be-the-tesla-of-transplants-heres-why-investors-are-paying-attention/" [X Link](https://x.com/BioTechHealthX/status/1947252089869971685) 2025-07-21T11:07Z [---] followers, [----] engagements "$MEDP Medpace shocked Wall Street with a record-breaking earnings beat & stock surge. This clinical trial powerhouse could be your next big winner. https://biotechhealthx.com/biotech-news/medpace-medp-just-soared-50-is-this-the-most-underrated-biotech-play-of-2025/ https://biotechhealthx.com/biotech-news/medpace-medp-just-soared-50-is-this-the-most-underrated-biotech-play-of-2025/" [X Link](https://x.com/BioTechHealthX/status/1947696100858888542) 2025-07-22T16:31Z [---] followers, [--] engagements "$MCRB Investors are eyeing Seres Therapeutics after its Vowst approval and SER-155 breakthrough. This could be the best kept secret in healthcare. https://biotechhealthx.com/biotech-news/seres-therapeutics-mcrb-the-100m-microbiome-gem-flying-under-wall-streets-radar/ https://biotechhealthx.com/biotech-news/seres-therapeutics-mcrb-the-100m-microbiome-gem-flying-under-wall-streets-radar/" [X Link](https://x.com/BioTechHealthX/status/1947696395991060535) 2025-07-22T16:33Z [---] followers, [---] engagements "$KRYS With the first redosable gene therapy approved by the FDA & a pipeline expanding into eye diseases @KrystalBiotech could breakout anytime https://biotechhealthx.com/biotech-news/krystal-biotech-krys-just-changed-gene-therapy-forever-smart-investors-are-paying-attention/ https://biotechhealthx.com/biotech-news/krystal-biotech-krys-just-changed-gene-therapy-forever-smart-investors-are-paying-attention/" [X Link](https://x.com/BioTechHealthX/status/1947696540635828616) 2025-07-22T16:33Z [---] followers, [---] engagements "$TMO Whether its research labs or vaccine production @thermofisher has its fingerprints on every major scientific innovation today. https://biotechhealthx.com/biotech-news/thermo-fisher-tmo-is-everywhere-and-thats-exactly-why-its-winning/ https://biotechhealthx.com/biotech-news/thermo-fisher-tmo-is-everywhere-and-thats-exactly-why-its-winning/" [X Link](https://x.com/BioTechHealthX/status/1948021410099761576) 2025-07-23T14:04Z [---] followers, [--] engagements "$MTVA With a bold rebrand and two clinical-stage assets MetaVia is chasing GLP-1 giants & eyeing FDA milestones. Investors should take notice now. https://biotechhealthx.com/biotech-news/from-neurobo-to-metavia-mtva-this-biotech-just-went-all-in-on-obesity-and-liver-disease/ https://biotechhealthx.com/biotech-news/from-neurobo-to-metavia-mtva-this-biotech-just-went-all-in-on-obesity-and-liver-disease/" [X Link](https://x.com/BioTechHealthX/status/1948021681601310813) 2025-07-23T14:05Z [---] followers, [---] engagements "$APLS With SYFOVRE sales surging & EMPAVELI awaiting FDA approval @ApellisPharma could explode in [----]. See why it could be the next breakout star. https://biotechhealthx.com/biotech-news/fda-decision-incoming-apellis-pharmaceuticals-apls-could-be-the-next-10x-biotech-stock/ https://biotechhealthx.com/biotech-news/fda-decision-incoming-apellis-pharmaceuticals-apls-could-be-the-next-10x-biotech-stock/" [X Link](https://x.com/BioTechHealthX/status/1949997661987213340) 2025-07-29T00:57Z [---] followers, [---] engagements "$URGN @UroGenPharma cancer therapies are shaking up uro-oncology. See why analysts predict massive growth & why investors are piling into URGN stock. https://biotechhealthx.com/biotech-news/wall-street-is-going-crazy-over-urogen-pharma-urgn-heres-why-it-could-be-a-2025-winner/ https://biotechhealthx.com/biotech-news/wall-street-is-going-crazy-over-urogen-pharma-urgn-heres-why-it-could-be-a-2025-winner/" [X Link](https://x.com/BioTechHealthX/status/1949998050136703209) 2025-07-29T00:58Z [---] followers, [---] engagements "$QNTM With a game-changing MS therapy a booming consumer product and insider confidence Quantum Biopharma could explode in [----]. https://biotechhealthx.com/biotech-news/wall-street-doesnt-want-you-to-see-this-stock-quantum-qntm-could-be-the-next-jackpot/ https://biotechhealthx.com/biotech-news/wall-street-doesnt-want-you-to-see-this-stock-quantum-qntm-could-be-the-next-jackpot/" [X Link](https://x.com/BioTechHealthX/status/1951351480147124661) 2025-08-01T18:37Z [---] followers, [--] engagements "$PHLT Performant Healthcare exploded as Machinify announced its acquisition. Heres how Performant Healthcare became a 3month success story. https://biotechhealthx.com/biotech-news/performant-healthcare-phlt-gets-670m-buyout-could-this-be-the-smartest-trade-of-2025/ https://biotechhealthx.com/biotech-news/performant-healthcare-phlt-gets-670m-buyout-could-this-be-the-smartest-trade-of-2025/" [X Link](https://x.com/BioTechHealthX/status/1951351638930919581) 2025-08-01T18:37Z [---] followers, [--] engagements "$NVO @teamnovonordisk shares have wiped out gains since Wegovys launch. This crash could be the perfect chance to buy before the next massive rally. https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-is-this-the-biggest-buying-opportunity-of-2025/ https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-is-this-the-biggest-buying-opportunity-of-2025/" [X Link](https://x.com/BioTechHealthX/status/1952182126952263715) 2025-08-04T01:37Z [---] followers, [---] engagements "$ADMA Analysts project billions in peak sales for ASCENIV as @AdmaBiologics scales production. Learn why Wall Street is going all in. https://biotechhealthx.com/biotech-news/adma-biologics-adma-could-be-the-next-billion-dollar-biotech-superstar/ https://biotechhealthx.com/biotech-news/adma-biologics-adma-could-be-the-next-billion-dollar-biotech-superstar/" [X Link](https://x.com/BioTechHealthX/status/1952182267335561342) 2025-08-04T01:38Z [---] followers, [---] engagements "$JNJ Institutions are snapping up @JNJNews shares as analysts predict strong gains. Learn why this Dividend King may be the ultimate [----] stock. https://biotechhealthx.com/biotech-news/the-secret-wall-street-play-why-big-money-is-buying-johnson-johnson-jnj/ https://biotechhealthx.com/biotech-news/the-secret-wall-street-play-why-big-money-is-buying-johnson-johnson-jnj/" [X Link](https://x.com/BioTechHealthX/status/1952182460449685689) 2025-08-04T01:39Z [---] followers, [--] engagements "$TNXP With positive Phase [--] trial data and a crucial PDUFA date coming soon Tonix Pharmaceuticals may be on the verge of a massive breakout. https://biotechhealthx.com/biotech-news/fda-approval-could-send-tonix-pharmaceuticals-tnxp-soaring-dont-miss-out/ https://biotechhealthx.com/biotech-news/fda-approval-could-send-tonix-pharmaceuticals-tnxp-soaring-dont-miss-out/" [X Link](https://x.com/BioTechHealthX/status/1952182592616480895) 2025-08-04T01:39Z [---] followers, [----] engagements "$FULC Pociredirs strong efficacy clean safety and massive potential market make Fulcrum one of the most exciting biotech plays right now. https://biotechhealthx.com/biotech-news/fulcrum-therapeutics-fulcs-stunning-trial-results-could-make-it-the-next-biotech-breakout/ https://biotechhealthx.com/biotech-news/fulcrum-therapeutics-fulcs-stunning-trial-results-could-make-it-the-next-biotech-breakout/" [X Link](https://x.com/BioTechHealthX/status/1952200658683392097) 2025-08-04T02:51Z [---] followers, [---] engagements "$HIMS Analysts are betting big on @himsandher as it targets $1.3B in EBITDA. See the growth blueprint behind this potential 10-bagger. https://biotechhealthx.com/biotech-news/hims-hers-hims-could-10x-by-2030-the-6-5-billion-bull-case-you-need-to-see/ https://biotechhealthx.com/biotech-news/hims-hers-hims-could-10x-by-2030-the-6-5-billion-bull-case-you-need-to-see/" [X Link](https://x.com/BioTechHealthX/status/1952752283315269879) 2025-08-05T15:23Z [---] followers, [--] engagements "$QBTS With a new AI toolkit and real-world quantum applications @dwavequantum is positioning itself to dominate a trillion-dollar future. Learn more here https://biotechhealthx.com/biotech-news/d-wave-qbts-just-changed-the-game-for-ai-and-their-stock-may-be-the-next-10x-winner/ https://biotechhealthx.com/biotech-news/d-wave-qbts-just-changed-the-game-for-ai-and-their-stock-may-be-the-next-10x-winner/" [X Link](https://x.com/BioTechHealthX/status/1952752509124235303) 2025-08-05T15:24Z [---] followers, [--] engagements "$NTRB @nutriband is closer than ever to changing the opioid industry. FDA filing is next and early investors are watching. https://biotechhealthx.com/biotech-news/nutriband-ntrb-the-1-biotech-that-could-10x-by-solving-americas-opioid-problem/ https://biotechhealthx.com/biotech-news/nutriband-ntrb-the-1-biotech-that-could-10x-by-solving-americas-opioid-problem/" [X Link](https://x.com/BioTechHealthX/status/1952752814654116226) 2025-08-05T15:25Z [---] followers, [---] engagements "$KYMR With KT-621 showing Dupixent-like results and a pipeline full of first-in-class therapies @kymera could be the biotech dream stock. https://biotechhealthx.com/biotech-news/2-3-billion-potential-why-kymera-therapeutics-kymr-might-be-the-biggest-sleeper-stock-in-biotech/ https://biotechhealthx.com/biotech-news/2-3-billion-potential-why-kymera-therapeutics-kymr-might-be-the-biggest-sleeper-stock-in-biotech/" [X Link](https://x.com/BioTechHealthX/status/1953133953722007941) 2025-08-06T16:39Z [---] followers, [---] engagements "$CRNX Analysts are piling into @Crinetics as it disrupts rare disease treatment. Discover the stock with 132% upside before it goes mainstream. https://biotechhealthx.com/biotech-news/wall-streets-best-kept-biotech-secret-crinetics-crnx-could-be-the-next-10x-stock/ https://biotechhealthx.com/biotech-news/wall-streets-best-kept-biotech-secret-crinetics-crnx-could-be-the-next-10x-stock/" [X Link](https://x.com/BioTechHealthX/status/1953134208756687045) 2025-08-06T16:40Z [---] followers, [---] engagements "$LLY With its innovative pipeline and consistent financial success @EliLillyandCo is the pharmaceutical stock to watch. Find out why investors love it https://biotechhealthx.com/biotech-news/heres-why-eli-lilly-lly-is-the-pharma-stock-everyone-is-talking-about-right-now/ https://biotechhealthx.com/biotech-news/heres-why-eli-lilly-lly-is-the-pharma-stock-everyone-is-talking-about-right-now/" [X Link](https://x.com/BioTechHealthX/status/1953815130698813442) 2025-08-08T13:46Z [---] followers, [--] engagements "$RCEL @AvitaMedical's RECELL System has already made an impact and with expanding applications investors can expect big returns. See more here https://biotechhealthx.com/biotech-news/avita-medical-rcel-is-delivering-big-returns-for-early-investors-heres-why-you-should-buy-this-now/ https://biotechhealthx.com/biotech-news/avita-medical-rcel-is-delivering-big-returns-for-early-investors-heres-why-you-should-buy-this-now/" [X Link](https://x.com/BioTechHealthX/status/1953815313818300675) 2025-08-08T13:47Z [---] followers, [---] engagements "$KURA @kuraoncology's ZIFTOMENIB is poised to become a breakthrough drug in the treatment of acute myeloid leukemia (AML). Learn about it more here https://biotechhealthx.com/biotech-news/kura-oncology-kuras-targeted-therapies-could-dominate-the-market/ https://biotechhealthx.com/biotech-news/kura-oncology-kuras-targeted-therapies-could-dominate-the-market/" [X Link](https://x.com/BioTechHealthX/status/1953815545406796021) 2025-08-08T13:48Z [---] followers, [---] engagements "$VSTM @VerastemOncolog 's targeted therapies are offering hope for patients with limited treatment options. Learn how it can change the game for cancer care. https://biotechhealthx.com/biotech-news/heres-why-verastem-vstm-is-the-next-big-thing-in-oncology/ https://biotechhealthx.com/biotech-news/heres-why-verastem-vstm-is-the-next-big-thing-in-oncology/" [X Link](https://x.com/BioTechHealthX/status/1953831365796872688) 2025-08-08T14:51Z [---] followers, [---] engagements "$ASMB Discover how Assembly Biosciences is revolutionizing chronic viral disease treatments with cutting-edge therapeutics targeting HBV HDV etc. https://biotechhealthx.com/biotech-news/assembly-bio-asmb-the-future-of-chronic-viral-disease-treatment-is-here/ https://biotechhealthx.com/biotech-news/assembly-bio-asmb-the-future-of-chronic-viral-disease-treatment-is-here/" [X Link](https://x.com/BioTechHealthX/status/1953831519060955245) 2025-08-08T14:51Z [---] followers, [---] engagements "$SLDB Solid Biosciences is developing the next-generation gene therapy for Duchenne muscular dystrophy with SGT-003 showing strong early results. https://biotechhealthx.com/biotech-news/the-future-of-gene-therapy-is-here-with-solid-biosciences-sldb-a-look-at-sgt-003/ https://biotechhealthx.com/biotech-news/the-future-of-gene-therapy-is-here-with-solid-biosciences-sldb-a-look-at-sgt-003/" [X Link](https://x.com/BioTechHealthX/status/1953831822271688892) 2025-08-08T14:53Z [---] followers, [---] engagements "$TRIB From cutting-edge diagnostics to real-time health monitoring @TrinityBiotech's global expansion & tech pivot could send its growth soaring. https://biotechhealthx.com/biotech-news/trinity-biotech-trib-could-be-the-next-billion-dollar-healthcare-innovator/ https://biotechhealthx.com/biotech-news/trinity-biotech-trib-could-be-the-next-billion-dollar-healthcare-innovator/" [X Link](https://x.com/BioTechHealthX/status/1956024368758452516) 2025-08-14T16:05Z [---] followers, [--] engagements "$RSLS Discover how the union of @ReShapeLifesci's obesity solutions and @VyomeTx's biotech pipeline could disrupt multi-billion-dollar markets worldwide. https://biotechhealthx.com/biotech-news/reshape-lifesciences-vyome-merger-could-create-a-healthcare-powerhouse/ https://biotechhealthx.com/biotech-news/reshape-lifesciences-vyome-merger-could-create-a-healthcare-powerhouse/" [X Link](https://x.com/BioTechHealthX/status/1956024819625157106) 2025-08-14T16:07Z [---] followers, [--] engagements "$IMAB I-Mabs innovative drug pipeline & strategic alliances could make it one of the most explosive growth stories in healthcare. https://biotechhealthx.com/biotech-news/why-i-mab-imab-could-be-the-next-big-breakout-in-global-biotech/ https://biotechhealthx.com/biotech-news/why-i-mab-imab-could-be-the-next-big-breakout-in-global-biotech/" [X Link](https://x.com/BioTechHealthX/status/1956024997207793679) 2025-08-14T16:07Z [---] followers, [---] engagements "$CVKD Tecarfarins unique design and regulatory fast-track status could make Cadrenal the most exciting growth story in biopharma right now. https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-inc-nasdaqcvkd/ https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-inc-nasdaqcvkd/" [X Link](https://x.com/BioTechHealthX/status/1956025563673714946) 2025-08-14T16:10Z [---] followers, [--] engagements "$CVM @CelSciCorp is on the verge of making Multikine available in Saudi Arabia within [--] days. This move could skyrocket the companys growth. https://biotechhealthx.com/biotech-news/saudi-arabia-deal-could-catapult-cel-sci-cvm-into-global-biotech-spotlight/ https://biotechhealthx.com/biotech-news/saudi-arabia-deal-could-catapult-cel-sci-cvm-into-global-biotech-spotlight/" [X Link](https://x.com/BioTechHealthX/status/1957247374881104199) 2025-08-18T01:05Z [---] followers, [---] engagements "$NERV Minerva Neurosciences engages the FDA for its pivotal trial potentially reshaping treatment for negative symptoms of schizophrenia. https://biotechhealthx.com/biotech-news/schizophrenia-breakthrough-alert-minerva-neurosciences-nervs-roluperidone-gains-fda-attention/ https://biotechhealthx.com/biotech-news/schizophrenia-breakthrough-alert-minerva-neurosciences-nervs-roluperidone-gains-fda-attention/" [X Link](https://x.com/BioTechHealthX/status/1957247504686129252) 2025-08-18T01:05Z [---] followers, [--] engagements "$CYCN @Cyclerion is transforming its sGC stimulator portfolio into a revenue powerhouse while building a next-generation CNS pipeline. https://biotechhealthx.com/biotech-news/cyclerion-therapeutics-cycn-poised-for-massive-growth-with-1-75m-license-deal/ https://biotechhealthx.com/biotech-news/cyclerion-therapeutics-cycn-poised-for-massive-growth-with-1-75m-license-deal/" [X Link](https://x.com/BioTechHealthX/status/1957406942953165225) 2025-08-18T11:39Z [---] followers, [---] engagements "$OTLK With a resubmitted BLA and prior EU approval Outlook Therapeutics could revolutionize wet AMD treatment. Learn about it more here https://biotechhealthx.com/biotech-news/will-lytenava-make-history-outlook-therapeutics-otlks-big-fda-moment-approaches/ https://biotechhealthx.com/biotech-news/will-lytenava-make-history-outlook-therapeutics-otlks-big-fda-moment-approaches/" [X Link](https://x.com/BioTechHealthX/status/1957407216912244755) 2025-08-18T11:40Z [---] followers, [---] engagements "$BSX Boston Scientific is being hailed as a forever stock with unstoppable growth in AI cardiology and global markets. Learn more here https://biotechhealthx.com/biotech-news/analysts-call-boston-scientific-bsx-a-forever-company-for-investors/ https://biotechhealthx.com/biotech-news/analysts-call-boston-scientific-bsx-a-forever-company-for-investors/" [X Link](https://x.com/BioTechHealthX/status/1958232155689275620) 2025-08-20T18:18Z [---] followers, [--] engagements "$JNJ Despite its strong brand and market dominance @JNJNews premium valuation may crumble under regulatory and legal weight. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-trading-near-highs-but-analysts-warn-of-a-reality-check/ https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-trading-near-highs-but-analysts-warn-of-a-reality-check/" [X Link](https://x.com/BioTechHealthX/status/1958232337415913765) 2025-08-20T18:19Z [---] followers, [--] engagements "$PVLA With a strong pipeline and insider ownership @PalvellaTX is quickly becoming one of the most promising biotech stocks of [----]. https://biotechhealthx.com/biotech-news/investors-are-betting-big-on-palvella-therapeutics-pvla/ https://biotechhealthx.com/biotech-news/investors-are-betting-big-on-palvella-therapeutics-pvla/" [X Link](https://x.com/BioTechHealthX/status/1959523485417427165) 2025-08-24T07:49Z [---] followers, [---] engagements "$KALA With KPI-012 data looming and only a year of cash left @KalaPharma future hangs by a thread. Could [----] be its last chance https://biotechhealthx.com/biotech-news/kala-pharma-kala-faces-make-or-break-2025-will-it-survive/ https://biotechhealthx.com/biotech-news/kala-pharma-kala-faces-make-or-break-2025-will-it-survive/" [X Link](https://x.com/BioTechHealthX/status/1959625833737523659) 2025-08-24T14:36Z [---] followers, [---] engagements "$MRNA Once a pandemic hero @moderna_tx now faces collapsing demand political pressure and mounting losses. Can this biotech giant survive https://biotechhealthx.com/biotech-news/moderna-mrna-crashes-90-from-highs/ https://biotechhealthx.com/biotech-news/moderna-mrna-crashes-90-from-highs/" [X Link](https://x.com/BioTechHealthX/status/1960137005301727377) 2025-08-26T00:27Z [---] followers, [--] engagements "$SLRX The Decoy Therapeutics merger adds more complexity but doesnt fix Salarius Pharmaceuticals' financial weaknesses dilution risks and regulatory problems. https://biotechhealthx.com/biotech-news/salarius-pharmaceuticals-slrx-merger-wont-save-it-from-trouble/ https://biotechhealthx.com/biotech-news/salarius-pharmaceuticals-slrx-merger-wont-save-it-from-trouble/" [X Link](https://x.com/BioTechHealthX/status/1960521554527420752) 2025-08-27T01:55Z [---] followers, [---] engagements "$SER Analysts see Serina Therapeutics surging as its unique POZ technology delivers long-acting therapies for neurological diseases with huge unmet need. https://biotechhealthx.com/biotech-news/wall-street-predicts-130-upside-for-serina-therapeutics-ser/ https://biotechhealthx.com/biotech-news/wall-street-predicts-130-upside-for-serina-therapeutics-ser/" [X Link](https://x.com/BioTechHealthX/status/1961246898490081653) 2025-08-29T01:57Z [---] followers, [--] engagements "$CRNX Wall Street is betting big on @Crinetics with strong buy ratings and price targets that more than double its current share price. Heres why. https://biotechhealthx.com/biotech-news/analysts-predict-over-100-upside-by-2026-for-crinetics-pharma-crnx/ https://biotechhealthx.com/biotech-news/analysts-predict-over-100-upside-by-2026-for-crinetics-pharma-crnx/" [X Link](https://x.com/BioTechHealthX/status/1961247107991425422) 2025-08-29T01:58Z [---] followers, [---] engagements "$PHAT Voquezna is @phathompharma only approved drug carrying both massive upside & massive risk. Wall Street is divided on the companys future. https://biotechhealthx.com/biotech-news/phathom-pharma-phats-future-hangs-on-a-single-pill/ https://biotechhealthx.com/biotech-news/phathom-pharma-phats-future-hangs-on-a-single-pill/" [X Link](https://x.com/BioTechHealthX/status/1961247368361177138) 2025-08-29T01:59Z [---] followers, [--] engagements "$EBS @EmergBsolutions secured $30M in BARDA funding but weak revenues and past scandals suggest investors should brace for more downside. https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-could-keep-sinking-despite-new-contracts/ https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-could-keep-sinking-despite-new-contracts/" [X Link](https://x.com/BioTechHealthX/status/1963297109685506094) 2025-09-03T17:44Z [---] followers, [---] engagements "$AUPH After hitting new highs @AuriniaPharma's revenue growth profitability and biotech pipeline suggest even greater upside for investors ahead. https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-52-week-high/ https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-52-week-high/" [X Link](https://x.com/BioTechHealthX/status/1963820349205925916) 2025-09-05T04:23Z [---] followers, [---] engagements "$IDYA With $210M upfront and $320M milestones Ideaya and Servier push for global approval of darovasertib in uveal melanoma. https://biotechhealthx.com/biotech-news/ideaya-idyas-530m-servier-deal-could-transform-cancer-care/ https://biotechhealthx.com/biotech-news/ideaya-idyas-530m-servier-deal-could-transform-cancer-care/" [X Link](https://x.com/BioTechHealthX/status/1964732244020617709) 2025-09-07T16:47Z [---] followers, [---] engagements "$ACET @AdicetBio ended Q1 [----] with $150.4M in cash but faces rising losses of $28.2M. Can it last long enough for its Phase [--] CAR T data to deliver https://biotechhealthx.com/biotech-news/adicet-acet-falls-despite-150-4m-cash-runway-into-2026/ https://biotechhealthx.com/biotech-news/adicet-acet-falls-despite-150-4m-cash-runway-into-2026/" [X Link](https://x.com/BioTechHealthX/status/1967864238225100924) 2025-09-16T08:12Z [---] followers, [---] engagements "$SLS @SellasLife raises $23.6M through warrant exercises boosting cash runway as GPS immunotherapy enters Phase [--] & SLS009 prepares for AML expansion. https://biotechhealthx.com/biotech-news/sellas-life-sls-secures-23-6m-to-fuel-late-stage-cancer-trials/ https://biotechhealthx.com/biotech-news/sellas-life-sls-secures-23-6m-to-fuel-late-stage-cancer-trials/" [X Link](https://x.com/BioTechHealthX/status/1968332372371529931) 2025-09-17T15:13Z [---] followers, [---] engagements "$NVO @novonordisk plunged from $69 to $53.94 on July [--] [----]. Can the GLP-1 leader in Ozempic and Wegovy rebound in the $100B obesity market https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-21-83-in-one-day/ https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-21-83-in-one-day/" [X Link](https://x.com/BioTechHealthX/status/1968524805914902882) 2025-09-18T03:57Z [---] followers, [---] engagements "$UNH EPS for @UnitedHealthGrp is projected at just $2.87 this quarter down from $6.80 last year raising serious doubts about near-term performance. https://biotechhealthx.com/biotech-news/unitedhealth-unhs-q3-earnings-forecast-crashes-nearly-60/ https://biotechhealthx.com/biotech-news/unitedhealth-unhs-q3-earnings-forecast-crashes-nearly-60/" [X Link](https://x.com/BioTechHealthX/status/1968909325285351875) 2025-09-19T05:25Z [---] followers, [---] engagements "$OSCR Despite an EPS miss of -$0.89 @OscarHealth grew revenue 29% YoY fueling optimism for its digital-first insurance model and long-term gains. https://biotechhealthx.com/biotech-news/oscar-health-oscr-reports-2-86b-revenue-in-q2-2025/ https://biotechhealthx.com/biotech-news/oscar-health-oscr-reports-2-86b-revenue-in-q2-2025/" [X Link](https://x.com/BioTechHealthX/status/1968909476116705360) 2025-09-19T05:26Z [---] followers, [---] engagements "$NTLA With an average target price of $34.14 @intelliatx could more than double as gene editing therapies near pivotal data in [----]. https://biotechhealthx.com/biotech-news/analysts-see-127-upside-for-intellia-ntla-after-14-99-surge/ https://biotechhealthx.com/biotech-news/analysts-see-127-upside-for-intellia-ntla-after-14-99-surge/" [X Link](https://x.com/BioTechHealthX/status/1968909624616071468) 2025-09-19T05:26Z [---] followers, [---] engagements "$MTSR @MetseraInc surged after @pfizer offered $47.50 per share in cash42% above its $33 closeplus up to $22.50 more tied to performance. https://biotechhealthx.com/biotech-news/metsera-mtsr-shares-soar-on-pfizers-7-3b-buyout/ https://biotechhealthx.com/biotech-news/metsera-mtsr-shares-soar-on-pfizers-7-3b-buyout/" [X Link](https://x.com/BioTechHealthX/status/1970023212009553959) 2025-09-22T07:11Z [---] followers, [--] engagements "$HROW By capping patient costs at $59 @Harrowhealth removes affordability barriers boosting refill rates and fueling long-term revenue growth. https://biotechhealthx.com/biotech-news/harrow-health-hrow-gains-momentum-with-59-cap-on-out-of-pocket-costs/ https://biotechhealthx.com/biotech-news/harrow-health-hrow-gains-momentum-with-59-cap-on-out-of-pocket-costs/" [X Link](https://x.com/BioTechHealthX/status/1971601593079574562) 2025-09-26T15:43Z [---] followers, [--] engagements "$MLTX Patients on sonelokimab doubled response rates vs. placebo in hidradenitis suppurativa. Wall Street watches MoonLake Immunotherapeutics ahead of FDA talks. https://biotechhealthx.com/biotech-news/moonlake-mltxs-sonelokimab-crushes-phase-3-goals-with-35-response-rate-in-hs/ https://biotechhealthx.com/biotech-news/moonlake-mltxs-sonelokimab-crushes-phase-3-goals-with-35-response-rate-in-hs/" [X Link](https://x.com/BioTechHealthX/status/1972528541163221201) 2025-09-29T05:07Z [---] followers, [---] engagements "$NVO @novonordiskfond posted $48.5 billion in revenue for [----] fueled by soaring demand for Ozempic and Wegovy. Can NVO maintain growth into [----] https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-surges-as-ozempic-and-wegovy-drive-48-5b-in-2025-sales/ https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-surges-as-ozempic-and-wegovy-drive-48-5b-in-2025-sales/" [X Link](https://x.com/BioTechHealthX/status/1972528734109651256) 2025-09-29T05:07Z [---] followers, [---] engagements "$JNJ @JNJNews stock is up 22% this year yet analysts say it remains fairly valued with room to climb. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-up-22-in-2025/ https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-up-22-in-2025/" [X Link](https://x.com/BioTechHealthX/status/1972528880801161280) 2025-09-29T05:08Z [---] followers, [--] engagements "$PFE @pfizer announced a $70 billion investment in R&D and U.S. manufacturing a bold move to drive innovation after a 10% stock decline this year. https://biotechhealthx.com/biotech-news/pfizer-pfe-secures-70b-rd-push/ https://biotechhealthx.com/biotech-news/pfizer-pfe-secures-70b-rd-push/" [X Link](https://x.com/BioTechHealthX/status/1973256877367869900) 2025-10-01T05:21Z [---] followers, [--] engagements "$XLV Health Care ETF (XLV) has beaten the S&P [---] in over half of the past [--] years. Heres why Wall Street calls it the ultimate healthcare growth and defense ETF. https://biotechhealthx.com/biotech-news/health-care-select-sector-spdr-fund-nysexlv/ https://biotechhealthx.com/biotech-news/health-care-select-sector-spdr-fund-nysexlv/" [X Link](https://x.com/BioTechHealthX/status/1973257240745484334) 2025-10-01T05:22Z [---] followers, [--] engagements "$CRMD The $325$350M [----] revenue guidance shows CorMedixs transformation from a one-drug biotech into a diversified infectious disease leader. https://biotechhealthx.com/biotech-news/cormedix-crmd-revenue-to-hit-350m-after-melinta-buyout/ https://biotechhealthx.com/biotech-news/cormedix-crmd-revenue-to-hit-350m-after-melinta-buyout/" [X Link](https://x.com/BioTechHealthX/status/1973733960011374738) 2025-10-02T12:57Z [---] followers, [--] engagements "$NVAX @Novavax amends its @sanofi collaboration unlocking up to $200M plus $210M per vaccine milestone payments and ongoing royalties. https://biotechhealthx.com/biotech-news/novavax-nvax-expands-200m-sanofi-deal-with-matrix-m-adjuvant/ https://biotechhealthx.com/biotech-news/novavax-nvax-expands-200m-sanofi-deal-with-matrix-m-adjuvant/" [X Link](https://x.com/BioTechHealthX/status/1974022499802235013) 2025-10-03T08:03Z [---] followers, [---] engagements "$INSM FDA approves Brinsupri as the first therapy for NCFB. @Insmed rallies to $149.20 with Wall Street setting price targets as high as $240. https://biotechhealthx.com/biotech-news/insmed-insm-jumps-to-149-20-high-after-fda-approval-of-brinsupri/ https://biotechhealthx.com/biotech-news/insmed-insm-jumps-to-149-20-high-after-fda-approval-of-brinsupri/" [X Link](https://x.com/BioTechHealthX/status/1974022734050177053) 2025-10-03T08:04Z [---] followers, [---] engagements "$UNH @UnitedHealthGrp delivers $111.62 billion in revenue yet EPS falls short spotlighting margin challenges in a costly healthcare climate. https://biotechhealthx.com/biotech-news/unitedhealth-unh-posts-111-62b-q2-revenue-but-earnings-disappoint/ https://biotechhealthx.com/biotech-news/unitedhealth-unh-posts-111-62b-q2-revenue-but-earnings-disappoint/" [X Link](https://x.com/BioTechHealthX/status/1976828621403918451) 2025-10-11T01:54Z [---] followers, [---] engagements "$EBS Down from $1B in prior years @EmergentLabsHQ's trailing twelve-month revenue exposes how hard its recovery journey has become. https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-faces-investor-pressure-after-revenue-drops-to-0-81b-ttm/ https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-faces-investor-pressure-after-revenue-drops-to-0-81b-ttm/" [X Link](https://x.com/BioTechHealthX/status/1976828927424528709) 2025-10-11T01:55Z [---] followers, [---] engagements "$TNXP @TonixPharma shares fall despite FDA approval for Tonmya. Analysts say the sell-off could be a golden opportunity for long-term investors. https://biotechhealthx.com/biotech-news/tonix-pharmaceuticals-tnxp-plunges-20-after-fda-win/ https://biotechhealthx.com/biotech-news/tonix-pharmaceuticals-tnxp-plunges-20-after-fda-win/" [X Link](https://x.com/BioTechHealthX/status/1978047574411272323) 2025-10-14T10:37Z [---] followers, [---] engagements "$AGIO With PYRUKYND poised for label expansion and Phase [--] trial results ahead Agios Pharmaceuticals may deliver serious upside. https://biotechhealthx.com/biotech-news/agios-agio-could-explode-in-2025-and-its-not-just-hype/ https://biotechhealthx.com/biotech-news/agios-agio-could-explode-in-2025-and-its-not-just-hype/" [X Link](https://x.com/BioTechHealthX/status/1941912629884453040) 2025-07-06T17:30Z [---] followers, [---] engagements "$PHVS @pharvaris NV is targeting a massive untapped opportunity with its oral HAE therapy. Heres why early investors are buying in. https://biotechhealthx.com/biotech-news/pharvaris-phvs-the-300m-biotech-that-could-be-the-next-big-thing-in-pharma/ https://biotechhealthx.com/biotech-news/pharvaris-phvs-the-300m-biotech-that-could-be-the-next-big-thing-in-pharma/" [X Link](https://x.com/BioTechHealthX/status/1946414453765112121) 2025-07-19T03:39Z [---] followers, [--] engagements "$NATR With strong Q1 results a conservative outlook and global tailwinds Nature's Shine could be one of the best small-cap opportunities this year. https://biotechhealthx.com/biotech-news/natures-sunshine-natr-is-crushing-expectations-is-a-2025-rally-imminent/ https://biotechhealthx.com/biotech-news/natures-sunshine-natr-is-crushing-expectations-is-a-2025-rally-imminent/" [X Link](https://x.com/BioTechHealthX/status/1946979956816535836) 2025-07-20T17:06Z [---] followers, [--] engagements "$KTTA Backed by institutional money and a best-in-class drug candidate @PasitheaTx may be poised for liftoff. Explore the bullish case now. https://biotechhealthx.com/biotech-news/pasithea-therapeutics-ktta-just-raised-5-million-is-this-the-spark-it-needed/ https://biotechhealthx.com/biotech-news/pasithea-therapeutics-ktta-just-raised-5-million-is-this-the-spark-it-needed/" [X Link](https://x.com/BioTechHealthX/status/1946980263361454496) 2025-07-20T17:07Z [---] followers, [---] engagements "$ISRG Intuitive Surgical just proved real-time remote surgery is more than hype. Its da Vinci [--] sets the new gold standard in digital surgery. https://biotechhealthx.com/biotech-news/telesurgery-is-here-and-intuitive-surgical-isrg-owns-it/ https://biotechhealthx.com/biotech-news/telesurgery-is-here-and-intuitive-surgical-isrg-owns-it/" [X Link](https://x.com/BioTechHealthX/status/1947696251413401756) 2025-07-22T16:32Z [---] followers, [---] engagements "$ATHE With a Phase III design meeting on deck and $1.1B peak sales potential Alterity Therapeutics could be on the verge of a breakout run. https://biotechhealthx.com/biotech-news/alterity-therapeutics-athe-is-one-fda-meeting-away-from-a-major-breakout/ https://biotechhealthx.com/biotech-news/alterity-therapeutics-athe-is-one-fda-meeting-away-from-a-major-breakout/" [X Link](https://x.com/BioTechHealthX/status/1948021558162964878) 2025-07-23T14:05Z [---] followers, [---] engagements "$NAGE With groundbreaking NAD+ science and its first profitable quarter @niagenbio might be the stock that delivers huge returns in [----]. https://biotechhealthx.com/biotech-news/from-10-to-23-why-niagen-bioscience-nage-could-be-the-next-big-biotech-success-story/ https://biotechhealthx.com/biotech-news/from-10-to-23-why-niagen-bioscience-nage-could-be-the-next-big-biotech-success-story/" [X Link](https://x.com/BioTechHealthX/status/1949998215576568302) 2025-07-29T00:59Z [---] followers, [---] engagements "$DRMA Dermata is making waves with its late-stage acne treatment and strategic NASDAQ compliance moves. Learn more about DRMA stock here. https://biotechhealthx.com/biotech-news/drma-stock-alert-why-dermata-therapeutics-drma-could-be-the-hidden-biotech-gem-of-2025/ https://biotechhealthx.com/biotech-news/drma-stock-alert-why-dermata-therapeutics-drma-could-be-the-hidden-biotech-gem-of-2025/" [X Link](https://x.com/BioTechHealthX/status/1952200769022972039) 2025-08-04T02:51Z [---] followers, [---] engagements "$XCUR With new AML and multiple myeloma trials on the horizon @exicure's GPC-100 may change the game for blood cancer therapies. Learn more here https://biotechhealthx.com/biotech-news/exicure-xcurs-gpc-100-could-revolutionize-cancer-treatment-analysts-see-massive-upside-for-this-stock/ https://biotechhealthx.com/biotech-news/exicure-xcurs-gpc-100-could-revolutionize-cancer-treatment-analysts-see-massive-upside-for-this-stock/" [X Link](https://x.com/BioTechHealthX/status/1952200914686865684) 2025-08-04T02:52Z [---] followers, [---] engagements "$MIRM @mirumpharma is on fire with soaring revenues and new clinical wins. Analysts say the stock is still cheapheres why it could double soon. https://biotechhealthx.com/biotech-news/from-0-to-300m-in-sales-mirum-pharmaceuticals-mirms-wild-ride-is-just-beginning/ https://biotechhealthx.com/biotech-news/from-0-to-300m-in-sales-mirum-pharmaceuticals-mirms-wild-ride-is-just-beginning/" [X Link](https://x.com/BioTechHealthX/status/1953133835987951947) 2025-08-06T16:39Z [---] followers, [--] engagements "$SLGL Sol-Gel Technologies is on the brink of transforming skincare. This biotech company could redefine the future of dermatology treatments. https://biotechhealthx.com/biotech-news/can-sol-gel-technologies-slgl-become-the-next-big-name-in-dermatology/ https://biotechhealthx.com/biotech-news/can-sol-gel-technologies-slgl-become-the-next-big-name-in-dermatology/" [X Link](https://x.com/BioTechHealthX/status/1953831675177185395) 2025-08-08T14:52Z [---] followers, [---] engagements "$IBRX @ImmunityBio just hit a major milestone with its cancer-fighting drug ANKTIVA. Heres why analysts believe this could send the stock soaring https://biotechhealthx.com/biotech-news/heres-why-wall-street-is-suddenly-obsessed-with-immunitybio-ibrx/ https://biotechhealthx.com/biotech-news/heres-why-wall-street-is-suddenly-obsessed-with-immunitybio-ibrx/" [X Link](https://x.com/BioTechHealthX/status/1955320308820271247) 2025-08-12T17:27Z [---] followers, [----] engagements "$JAZZ The @Saniona_AB partnership gives @JazzPharma rights to SAN2355 a preclinical epilepsy drug. Is this a golden opportunity or a billion-dollar mistake https://biotechhealthx.com/biotech-news/jazz-pharmaceuticals-jazzs-latest-deal-could-make-or-break-its-entire-future/ https://biotechhealthx.com/biotech-news/jazz-pharmaceuticals-jazzs-latest-deal-could-make-or-break-its-entire-future/" [X Link](https://x.com/BioTechHealthX/status/1958231696844992654) 2025-08-20T18:16Z [---] followers, [---] engagements "$ZBH @zimmerbiomet stock jumped to $107.71 but repeated guidance cuts and operational risks suggest this rally may not last long. https://biotechhealthx.com/biotech-news/zimmer-biomet-zbhs-3-gain-could-be-a-trap-for-investors/ https://biotechhealthx.com/biotech-news/zimmer-biomet-zbhs-3-gain-could-be-a-trap-for-investors/" [X Link](https://x.com/BioTechHealthX/status/1959523289124184117) 2025-08-24T07:48Z [---] followers, [--] engagements "$LFVN @lifevantage expanded fast with its wellness products but investors are asking whether its MLM structure is sustainable. https://biotechhealthx.com/biotech-news/lifevantage-lfvn-faces-big-questions-despite-its-global-growth/ https://biotechhealthx.com/biotech-news/lifevantage-lfvn-faces-big-questions-despite-its-global-growth/" [X Link](https://x.com/BioTechHealthX/status/1959523899533603048) 2025-08-24T07:51Z [---] followers, [---] engagements "$CORT Despite analyst optimism @Corcept shares plunged. Learn what triggered the drop and why it could signal deeper problems for investors. https://biotechhealthx.com/biotech-news/corcept-therapeutics-cort-crashed-monday-is-this-the-start-of-a-bigger-selloff/ https://biotechhealthx.com/biotech-news/corcept-therapeutics-cort-crashed-monday-is-this-the-start-of-a-bigger-selloff/" [X Link](https://x.com/BioTechHealthX/status/1959625015135269095) 2025-08-24T14:33Z [---] followers, [--] engagements "$BBIO @BridgeBioPharma's pipeline looks strong but its rising expenses and insider sales raise red flags. Is BBIO headed for a crash https://biotechhealthx.com/biotech-news/bbio-stock-alert-can-bridgebio-pharma-survive-its-cash-burn/ https://biotechhealthx.com/biotech-news/bbio-stock-alert-can-bridgebio-pharma-survive-its-cash-burn/" [X Link](https://x.com/BioTechHealthX/status/1959628137526083910) 2025-08-24T14:45Z [---] followers, [---] engagements "$EVOK With limited cash rising debt and no diversification Evoke Pharma may be at breaking point. Investors should brace for downside risk. https://biotechhealthx.com/biotech-news/evoke-pharma-evok-faces-harsh-reality-can-it-avoid-collapse/ https://biotechhealthx.com/biotech-news/evoke-pharma-evok-faces-harsh-reality-can-it-avoid-collapse/" [X Link](https://x.com/BioTechHealthX/status/1959628284465180946) 2025-08-24T14:46Z [---] followers, [--] engagements "$SER Serina Therapeutics surged after FDA feedback on its Parkinsons candidate SER-252. Can this small-cap biotech turn into a billion-dollar winner https://biotechhealthx.com/biotech-news/serina-sers-parkinsons-drug-gets-fda-support-stock-investors-go-wild/ https://biotechhealthx.com/biotech-news/serina-sers-parkinsons-drug-gets-fda-support-stock-investors-go-wild/" [X Link](https://x.com/BioTechHealthX/status/1960136816461574239) 2025-08-26T00:26Z [---] followers, [--] engagements "$HCA @HCAhealthcare has soared from $123 to over $400 per share. With rising earnings estimates can HCA keep climbing higher https://biotechhealthx.com/biotech-news/hca-healthcare-hca-surges-over-228-since-2019/ https://biotechhealthx.com/biotech-news/hca-healthcare-hca-surges-over-228-since-2019/" [X Link](https://x.com/BioTechHealthX/status/1960350057712251122) 2025-08-26T14:34Z [---] followers, [---] engagements "$TTNP Titan Pharmaceuticals jumps on merger approval with Black Titan but poor financials weak cash runway and heavy dilution risks could crush long-term value. https://biotechhealthx.com/biotech-news/titan-pharmaceuticals-ttnp-merger-hype-vs-reality/ https://biotechhealthx.com/biotech-news/titan-pharmaceuticals-ttnp-merger-hype-vs-reality/" [X Link](https://x.com/BioTechHealthX/status/1960521301678023057) 2025-08-27T01:54Z [---] followers, [---] engagements "$RADX @TeamRadiopharm uplisted to @Nasdaq with bold cancer treatment ambitions but early pipeline risks and cash burn make RADX a speculative play. https://biotechhealthx.com/biotech-news/radiopharm-radx-stock-high-risk-high-hype/ https://biotechhealthx.com/biotech-news/radiopharm-radx-stock-high-risk-high-hype/" [X Link](https://x.com/BioTechHealthX/status/1960521957943992786) 2025-08-27T01:57Z [---] followers, [---] engagements "$GBIO With funding secured through [----] @generationbio has the runway to advance clinical trials without immediate dilution strengthening its bullish case. https://biotechhealthx.com/biotech-news/generation-bio-gbio-has-185m-in-cash-heres-why-that-matters/ https://biotechhealthx.com/biotech-news/generation-bio-gbio-has-185m-in-cash-heres-why-that-matters/" [X Link](https://x.com/BioTechHealthX/status/1960522130489270362) 2025-08-27T01:57Z [---] followers, [---] engagements "$MOH Medicaid redeterminations shrinking enrollments and rising costs could derail Molina Healthcares dominance in government healthcare programs. https://biotechhealthx.com/biotech-news/molina-healthcare-mohs-medicaid-empire-faces-its-toughest-test-yet/ https://biotechhealthx.com/biotech-news/molina-healthcare-mohs-medicaid-empire-faces-its-toughest-test-yet/" [X Link](https://x.com/BioTechHealthX/status/1961247829558780328) 2025-08-29T02:01Z [---] followers, [---] engagements "$TGTX With Briumvi sales projected to cross $1B by [----] @TGTherapeutics may be Wall Streets next biotech superstar. Heres the full story. https://biotechhealthx.com/biotech-news/tg-therapeutics-tgtx-can-be-the-next-1b-biotech-giant/ https://biotechhealthx.com/biotech-news/tg-therapeutics-tgtx-can-be-the-next-1b-biotech-giant/" [X Link](https://x.com/BioTechHealthX/status/1963296471840952715) 2025-09-03T17:42Z [---] followers, [----] engagements "$HQY @HealthEquity just reported massive profit growth & record margins. This healthcare savings stock may be primed for even bigger gains. https://biotechhealthx.com/biotech-news/healthequity-hqy-crushes-earnings-with-67-profit-surge/ https://biotechhealthx.com/biotech-news/healthequity-hqy-crushes-earnings-with-67-profit-surge/" [X Link](https://x.com/BioTechHealthX/status/1963297037275074846) 2025-09-03T17:44Z [---] followers, [--] engagements "$AVTX Avalo Therapeutics stock has jumped 45% in six months. With $113M cash Buy ratings and a $30 average target analysts project nearly 195% more upside. https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-surges-45-in-6-months/ https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-surges-45-in-6-months/" [X Link](https://x.com/BioTechHealthX/status/1963967996520788023) 2025-09-05T14:10Z [---] followers, [---] engagements "$AXSM @axsome reported $150M Q2 revenue with EPS of $0.92 vs $1 expected. Strong Auvelity sales drove 72% YoY growth but net loss hit $48. https://biotechhealthx.com/biotech-news/axsome-axsm-posts-150m-q2-revenue-beats-eps-expectations/ https://biotechhealthx.com/biotech-news/axsome-axsm-posts-150m-q2-revenue-beats-eps-expectations/" [X Link](https://x.com/BioTechHealthX/status/1963968356140318748) 2025-09-05T14:11Z [---] followers, [---] engagements "$OKYO @OkyoPharma's urcosimod delivered 75%+ pain reduction in neuropathic corneal pain patients and analyst upgrades with targets up to $8. https://biotechhealthx.com/biotech-news/okyo-pharma-okyo-surges-on-75-pain-reduction-in-phase-2-trial/ https://biotechhealthx.com/biotech-news/okyo-pharma-okyo-surges-on-75-pain-reduction-in-phase-2-trial/" [X Link](https://x.com/BioTechHealthX/status/1964743939854147595) 2025-09-07T17:33Z [---] followers, [---] engagements "$SPRO Spero Therapeutics shares skyrocketed over 200% after tebipenem HBr hit efficacy goals in a 1690-patient Phase [--] trial. https://biotechhealthx.com/biotech-news/spero-therapeutics-spro-surges-after-200-stock-jump-on-phase-3-success/ https://biotechhealthx.com/biotech-news/spero-therapeutics-spro-surges-after-200-stock-jump-on-phase-3-success/" [X Link](https://x.com/BioTechHealthX/status/1964744452632895645) 2025-09-07T17:35Z [---] followers, [---] engagements "$ADVM Analysts project @adverumbio Biotechnologies Inc. shares could climb from $3.52 to $19.75 with some targets as high as $33. https://biotechhealthx.com/biotech-news/adverum-advm-could-soar-460-with-19-75-target/ https://biotechhealthx.com/biotech-news/adverum-advm-could-soar-460-with-19-75-target/" [X Link](https://x.com/BioTechHealthX/status/1964744716601499888) 2025-09-07T17:36Z [---] followers, [---] engagements "$CRVS @CorvusPharma reported a net loss of $8M in Q2 [----] nearly double last years $4.3M. Can soquelitinibs early trial data offset rising R&D costs https://biotechhealthx.com/biotech-news/corvus-pharmaceuticals-inc-nasdaqcrvs/ https://biotechhealthx.com/biotech-news/corvus-pharmaceuticals-inc-nasdaqcrvs/" [X Link](https://x.com/BioTechHealthX/status/1966888193992868217) 2025-09-13T15:34Z [---] followers, [---] engagements "$NAGE Despite soaring 503% since [----] @niagenbio intrinsic value is only $4.04 per share. Is NAGE stock trading 133% above fair value https://biotechhealthx.com/biotech-news/niagen-bioscience-nage-up-503-in-3-years/ https://biotechhealthx.com/biotech-news/niagen-bioscience-nage-up-503-in-3-years/" [X Link](https://x.com/BioTechHealthX/status/1966888424767680975) 2025-09-13T15:35Z [---] followers, [---] engagements "$ABVC @ABVCBioPharma reported 103% growth to $16.2M in Q2 [----] with shareholder equity up 18.7%. Investors eye its oncology pipeline for upside. https://biotechhealthx.com/biotech-news/abvc-biopharma-abvc-doubles-assets-to-16-2m-in-q2-2025/ https://biotechhealthx.com/biotech-news/abvc-biopharma-abvc-doubles-assets-to-16-2m-in-q2-2025/" [X Link](https://x.com/BioTechHealthX/status/1967467823523045803) 2025-09-15T05:57Z [---] followers, [--] engagements "$MGTX @MeiraGTx posted a Q2 loss of ($0.48) EPS beat estimates by $0.04 with $3.69M revenue as late-stage programs fuel analyst optimism. https://biotechhealthx.com/biotech-news/meiragtx-mgtx-reports-3-69m-revenue/ https://biotechhealthx.com/biotech-news/meiragtx-mgtx-reports-3-69m-revenue/" [X Link](https://x.com/BioTechHealthX/status/1967863614112665622) 2025-09-16T08:10Z [---] followers, [---] engagements "$PHGE In Phase [--] trials @BiomX_Inc's BX211 showed a 40% wound size reduction in diabetic foot osteomyelitis. Can this make PHGE the next biotech champ https://biotechhealthx.com/biotech-news/biomx-phge-surges-as-bx211-cuts-diabetic-wounds-by-40/ https://biotechhealthx.com/biotech-news/biomx-phge-surges-as-bx211-cuts-diabetic-wounds-by-40/" [X Link](https://x.com/BioTechHealthX/status/1967863881281532151) 2025-09-16T08:11Z [---] followers, [---] engagements "$ENLV @EnlivexT narrowed its Q2 net loss to $1.87M from $3.1M last year reducing burn as Allocetra delivers strong clinical wins. https://biotechhealthx.com/biotech-news/enlivex-enlv-reports-1-87m-q2-loss-cuts-cash-burn-nearly-40/ https://biotechhealthx.com/biotech-news/enlivex-enlv-reports-1-87m-q2-loss-cuts-cash-burn-nearly-40/" [X Link](https://x.com/BioTechHealthX/status/1967864102895894990) 2025-09-16T08:12Z [---] followers, [--] engagements "$ZYME @ZymeworksInc delivered a 153.2% YoY revenue increase and surprised Wall Street with $0.03 EPS. Analysts now eye $21.43 per share. https://biotechhealthx.com/biotech-news/zymeworks-zyme-reports-153-revenue-growth-beats-eps-expectations/ https://biotechhealthx.com/biotech-news/zymeworks-zyme-reports-153-revenue-growth-beats-eps-expectations/" [X Link](https://x.com/BioTechHealthX/status/1970023408403632327) 2025-09-22T07:12Z [---] followers, [--] engagements "$FLGC @floragrowthcorp stock surged 69% after-hours as it rebrands to ZeroStack backing a $401M deal in AI and blockchain. https://biotechhealthx.com/biotech-news/flora-growth-flgc-soars-69-after-401m-ai-pivot/ https://biotechhealthx.com/biotech-news/flora-growth-flgc-soars-69-after-401m-ai-pivot/" [X Link](https://x.com/BioTechHealthX/status/1970023602750951755) 2025-09-22T07:13Z [---] followers, [--] engagements "$FGEN @FibroGenInc (NASDAQ:FGEN) offloads FibroGen China for $160M extending cash runway into [----] while focusing on oncology trials. https://biotechhealthx.com/biotech-news/fibrogen-fgen-sells-china-arm-to-astrazeneca-in-160m-deal/ https://biotechhealthx.com/biotech-news/fibrogen-fgen-sells-china-arm-to-astrazeneca-in-160m-deal/" [X Link](https://x.com/BioTechHealthX/status/1970023764772745719) 2025-09-22T07:14Z [---] followers, [--] engagements "$SLNO Soleno plunged 26% in a month after a short-seller attack but analysts still target $110$120. Is this oversold stock ready to rebound https://biotechhealthx.com/biotech-news/soleno-slno-oversold-after-26-drop/ https://biotechhealthx.com/biotech-news/soleno-slno-oversold-after-26-drop/" [X Link](https://x.com/BioTechHealthX/status/1970888477777842333) 2025-09-24T16:30Z [---] followers, [--] engagements "$BCTX Fresh capital fuels @BriaCell's pipeline including Bria-IMT and Bria-OTS+ as it accelerates clinical trials in breast and prostate cancer. https://biotechhealthx.com/biotech-news/briacell-bctx-raises-13-8m-to-advance-cancer-immunotherapy-pipeline/ https://biotechhealthx.com/biotech-news/briacell-bctx-raises-13-8m-to-advance-cancer-immunotherapy-pipeline/" [X Link](https://x.com/BioTechHealthX/status/1971259324552061432) 2025-09-25T17:03Z [---] followers, [---] engagements "$QLGN @Qualigen locks in a $41M PIPE from Faraday Future at $2.246/share. Will its oncology pipeline & crypto pivot drive the next biotech breakout https://biotechhealthx.com/biotech-news/qualigen-therapeutics-qlgn-secures-41m-faraday-future-deal/ https://biotechhealthx.com/biotech-news/qualigen-therapeutics-qlgn-secures-41m-faraday-future-deal/" [X Link](https://x.com/BioTechHealthX/status/1971259482819977271) 2025-09-25T17:04Z [---] followers, [--] engagements "$SMMT Summit Therapeutics gained 14% this year as ivonescimab showed global trial success. Can it deliver the next big oncology breakthrough https://biotechhealthx.com/biotech-news/summit-therapeutics-smmt-up-14-ytd/ https://biotechhealthx.com/biotech-news/summit-therapeutics-smmt-up-14-ytd/" [X Link](https://x.com/BioTechHealthX/status/1972183765490585619) 2025-09-28T06:17Z [---] followers, [---] engagements "$HUM @Humana hit with $32 million legal fee order after $90M settlement whats next for the $60B healthcare giant https://biotechhealthx.com/biotech-news/humana-hum-ordered-to-pay-32-million-in-whistleblower-case/ https://biotechhealthx.com/biotech-news/humana-hum-ordered-to-pay-32-million-in-whistleblower-case/" [X Link](https://x.com/BioTechHealthX/status/1972528994399695312) 2025-09-29T05:08Z [---] followers, [--] engagements "$AUPH @AuriniaPharma rockets to a 52-week high at $13.45 capping an 80.56% one-year gain. Strong Q2 earnings and 80% margins fuel investor optimism. https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-13-45-52-week-high-after-80-surge/ https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-13-45-52-week-high-after-80-surge/" [X Link](https://x.com/BioTechHealthX/status/1972888044475982085) 2025-09-30T04:55Z [---] followers, [---] engagements "$FDMT CLO Scott Bizily sells $19256 in @4DMolecular shares but stock surged 27% this week. As Phase [--] trials begin is Goldmans $38 target next https://biotechhealthx.com/biotech-news/4d-molecular-therapeutics-insider-sells-19256-as-fdmt-surges-27-in-a-week/ https://biotechhealthx.com/biotech-news/4d-molecular-therapeutics-insider-sells-19256-as-fdmt-surges-27-in-a-week/" [X Link](https://x.com/BioTechHealthX/status/1972888311099498708) 2025-09-30T04:56Z [---] followers, [---] engagements "$CVKD Cadrenal surged after acquiring frunexian a Phase 2-ready Factor XIa inhibitor. Analysts keep $30/share valuation despite early-stage risks. https://biotechhealthx.com/biotech-news/cadrenal-cvkd-targeted-at-30-after-acquiring-phase-2-ready-frunexian/ https://biotechhealthx.com/biotech-news/cadrenal-cvkd-targeted-at-30-after-acquiring-phase-2-ready-frunexian/" [X Link](https://x.com/BioTechHealthX/status/1973257081202548898) 2025-10-01T05:22Z [---] followers, [--] engagements "$CORT @Corcept has delivered a jaw-dropping 1534% gain in the last decade. With FDA review of relacorilant underway can this stock keep climbing https://biotechhealthx.com/biotech-news/corcept-cort-skyrockets-1534-in-10-years/ https://biotechhealthx.com/biotech-news/corcept-cort-skyrockets-1534-in-10-years/" [X Link](https://x.com/BioTechHealthX/status/1973257534648754501) 2025-10-01T05:23Z [---] followers, [---] engagements "$HALO With $1.179B in trailing revenue and royalties surging 65% YoY @halozymeinc is turning its ENHANZE platform into a biotech money engine. https://biotechhealthx.com/biotech-news/halozyme-halo-reports-1-179b-revenue-and-65-royalty-growth/ https://biotechhealthx.com/biotech-news/halozyme-halo-reports-1-179b-revenue-and-65-royalty-growth/" [X Link](https://x.com/BioTechHealthX/status/1973733785381577199) 2025-10-02T12:56Z [---] followers, [---] engagements "$KZIA Despite working on glioblastoma & DIPG with median survival under [--] months Kazia trades below $1. Is Wall Street overlooking this stock https://biotechhealthx.com/biotech-news/kazia-kzia-trades-under-1-while-tackling-cancers-with-1-year-survival-rates/ https://biotechhealthx.com/biotech-news/kazia-kzia-trades-under-1-while-tackling-cancers-with-1-year-survival-rates/" [X Link](https://x.com/BioTechHealthX/status/1973734520143945900) 2025-10-02T12:59Z [---] followers, [---] engagements "$DRMA Dermata secures Australian patent for its Spongilla-based acne treatment targeting [---] million acne patients. OTC launch set for mid-2026. https://biotechhealthx.com/biotech-news/dermata-drma-wins-australian-patent-for-acne-therapy/ https://biotechhealthx.com/biotech-news/dermata-drma-wins-australian-patent-for-acne-therapy/" [X Link](https://x.com/BioTechHealthX/status/1973734647415877956) 2025-10-02T12:59Z [---] followers, [---] engagements "$RXRX Needham analyst Gil Blum reiterated a Buy on @RecursionPharma with a $8 target highlighting AI partnerships and a growing clinical pipeline. https://biotechhealthx.com/biotech-news/recursion-pharmaceuticals-stock-could-double-with-8-price-target/ https://biotechhealthx.com/biotech-news/recursion-pharmaceuticals-stock-could-double-with-8-price-target/" [X Link](https://x.com/BioTechHealthX/status/1974022198722769406) 2025-10-03T08:02Z [---] followers, [---] engagements "$NCNA @NuCana_news just removed all Series A Warrants improving financial clarity and positioning itself for major [----] milestone results. https://biotechhealthx.com/biotech-news/nucana-ncna-completes-3-6m-warrant-buyout/ https://biotechhealthx.com/biotech-news/nucana-ncna-completes-3-6m-warrant-buyout/" [X Link](https://x.com/BioTechHealthX/status/1975612743068885338) 2025-10-07T17:22Z [---] followers, [---] engagements "$CADL Analysts see Candel Therapeutics hitting $20.06272% higher than $5.39on viral immunotherapy breakthroughs led by CAN-2409 and CAN-3110. https://biotechhealthx.com/biotech-news/candel-therapeutics-cadl-poised-for-272-upside/ https://biotechhealthx.com/biotech-news/candel-therapeutics-cadl-poised-for-272-upside/" [X Link](https://x.com/BioTechHealthX/status/1976142701239337298) 2025-10-09T04:28Z [---] followers, [---] engagements "$CRSP Analysts project massive upside as CRISPR Therapeutics Casgevy becomes the first gene-editing cure for sickle-cell and thalassemia. https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/ https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/" [X Link](https://x.com/BioTechHealthX/status/1976142843384299896) 2025-10-09T04:29Z [---] followers, [---] engagements "$CRSP Analysts project massive upside as CRISPR Therapeutics Casgevy becomes the first gene-editing cure for sickle-cell and thalassemia. https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/ https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/" [X Link](https://x.com/BioTechHealthX/status/1976143033772003673) 2025-10-09T04:29Z [---] followers, [---] engagements "$REGN The Phase [--] C-POST trial proved Libtayo cut cancer recurrence risk by 68% yet @Regeneron tumbled 3%. What spooked investors https://biotechhealthx.com/biotech-news/regeneron-regns-68-efficacy-breakthrough-fails-to-impress-wall-street/ https://biotechhealthx.com/biotech-news/regeneron-regns-68-efficacy-breakthrough-fails-to-impress-wall-street/" [X Link](https://x.com/BioTechHealthX/status/1976143068140347784) 2025-10-09T04:29Z [---] followers, [--] engagements "$TPST With $14.3M in cash Tempest Therapeutics strengthens its position before launching its most ambitious liver cancer study yet. https://biotechhealthx.com/biotech-news/tempest-therapeutics-tpst-boosts-cash-with-4-6m-raise-ahead-of-cancer-trial/ https://biotechhealthx.com/biotech-news/tempest-therapeutics-tpst-boosts-cash-with-4-6m-raise-ahead-of-cancer-trial/" [X Link](https://x.com/BioTechHealthX/status/1976143268565184808) 2025-10-09T04:30Z [---] followers, [---] engagements "$ELV Trading at just [-----] forward earnings vs. the industrys [----] @ElevanceHealth's strategy could offer a major rebound opportunity. https://biotechhealthx.com/biotech-news/elevance-health-elv-down-14-6-ytd/ https://biotechhealthx.com/biotech-news/elevance-health-elv-down-14-6-ytd/" [X Link](https://x.com/BioTechHealthX/status/1976143799165624453) 2025-10-09T04:32Z [---] followers, [--] engagements "$ARGX @argenxglobal soared to $803.95 fueled by 88% year-over-year revenue growth and record Vyvgart sales. Can the $45B biotech keep its momentum https://biotechhealthx.com/biotech-news/argenx-se-argx-hits-803-95-all-time-high-after-88-revenue-surge/ https://biotechhealthx.com/biotech-news/argenx-se-argx-hits-803-95-all-time-high-after-88-revenue-surge/" [X Link](https://x.com/BioTechHealthX/status/1976237900292661498) 2025-10-09T10:46Z [---] followers, [---] engagements "$ACON Out of [----] digital health innovators @aclarioninc Nociscan shines as a finalist in the Clinical Diagnostic Device category at HLTH [----]. https://biotechhealthx.com/biotech-news/aclarion-acon-emerges-as-rising-star-in-ai-diagnostics-at-hlth-2025-awards/ https://biotechhealthx.com/biotech-news/aclarion-acon-emerges-as-rising-star-in-ai-diagnostics-at-hlth-2025-awards/" [X Link](https://x.com/BioTechHealthX/status/1976828774173098307) 2025-10-11T01:54Z [---] followers, [---] engagements "$AXGN Revenue jumped 17.4% year-over-year as Axogen nears its FDA BLA decision. Analysts project up to 60% upside before the December [--] ruling. https://biotechhealthx.com/biotech-news/axogen-axgn-surges-toward-26-target-as-nerve-repair-demand-soars-17/ https://biotechhealthx.com/biotech-news/axogen-axgn-surges-toward-26-target-as-nerve-repair-demand-soars-17/" [X Link](https://x.com/BioTechHealthX/status/1977420465649115281) 2025-10-12T17:05Z [---] followers, [--] engagements "$LH With EPS set to jump 82% this year investors see upside for @Labcorp's $19.5B diagnostics empire. https://biotechhealthx.com/biotech-news/labcorp-lh-trades-near-210-as-investors-bet-on-82-earnings-boom/ https://biotechhealthx.com/biotech-news/labcorp-lh-trades-near-210-as-investors-bet-on-82-earnings-boom/" [X Link](https://x.com/BioTechHealthX/status/1977421022988308755) 2025-10-12T17:08Z [---] followers, [--] engagements "$ALDX @AldeyraALDX's shares dip under $5.40 ahead of the December [--] FDA ruling on reproxalap will approval save the company https://biotechhealthx.com/biotech-news/aldeyra-therapeutics-aldx-falls-below-5-40-as-fda-decision-looms/ https://biotechhealthx.com/biotech-news/aldeyra-therapeutics-aldx-falls-below-5-40-as-fda-decision-looms/" [X Link](https://x.com/BioTechHealthX/status/1977421347866431730) 2025-10-12T17:09Z [---] followers, [---] engagements "$GALT With belapectin showing a 49% reduction in varices @GalectinGALT targets a massive untapped market with no approved therapies. https://biotechhealthx.com/biotech-news/inside-galectin-galts-18-billion-shot-at-reversing-liver-cirrhosis/ https://biotechhealthx.com/biotech-news/inside-galectin-galts-18-billion-shot-at-reversing-liver-cirrhosis/" [X Link](https://x.com/BioTechHealthX/status/1977804258608349247) 2025-10-13T18:30Z [---] followers, [---] engagements "$TENX With $105.5M in cash @TenaxThera is advancing two Phase [--] trials that could deliver the first therapy for PH-HFpEF by [----]. https://biotechhealthx.com/biotech-news/tenax-therapeutics-tenx-fully-funded-through-2027-with-105-5m-cash/ https://biotechhealthx.com/biotech-news/tenax-therapeutics-tenx-fully-funded-through-2027-with-105-5m-cash/" [X Link](https://x.com/BioTechHealthX/status/1977804788218896558) 2025-10-13T18:33Z [---] followers, [---] engagements "$MOH Molina Healthcares shares plunged 39.31% in [--] months after cutting EPS guidance amid soaring medical costs. Is a turnaround possible https://biotechhealthx.com/biotech-news/molina-healthcare-moh-crashes-39-in-a-year/ https://biotechhealthx.com/biotech-news/molina-healthcare-moh-crashes-39-in-a-year/" [X Link](https://x.com/BioTechHealthX/status/1978047106062684517) 2025-10-14T10:35Z [---] followers, [---] engagements "$AZN @AstraZeneca eyes $80B in annual revenue by [----] driven by [--] new drug launches and booming oncology sales. https://biotechhealthx.com/biotech-news/astrazeneca-azn-targets-80-billion-revenue-by-2030/ https://biotechhealthx.com/biotech-news/astrazeneca-azn-targets-80-billion-revenue-by-2030/" [X Link](https://x.com/BioTechHealthX/status/1978047447760015442) 2025-10-14T10:37Z [---] followers, [--] engagements "$TDOC After its $18.5B Livongo deal @TeladocHealth's new AI system positions it as the leader in next-gen hospital safety and virtual care. https://biotechhealthx.com/biotech-news/teladoc-tdocs-ai-upgrade-could-be-its-biggest-breakthrough-since-livongo/ https://biotechhealthx.com/biotech-news/teladoc-tdocs-ai-upgrade-could-be-its-biggest-breakthrough-since-livongo/" [X Link](https://x.com/BioTechHealthX/status/1978440534893936950) 2025-10-15T12:39Z [---] followers, [---] engagements "$RADX @TeamRadiopharm shares paused before key capital raise to fund Phase [--] cancer trials market cap A$85.1M. https://biotechhealthx.com/biotech-news/radiopharm-theranostics-radx-halts-trading-ahead-of-major-capital-raise/ https://biotechhealthx.com/biotech-news/radiopharm-theranostics-radx-halts-trading-ahead-of-major-capital-raise/" [X Link](https://x.com/BioTechHealthX/status/1978440898296860788) 2025-10-15T12:40Z [---] followers, [---] engagements "$TEVA The FDA just expanded UZEDYs use to bipolar I disorder giving @TevaPharmaDC access to a $4.X.5B U.S. psychiatric market. https://biotechhealthx.com/biotech-news/teva-pharma-teva-wins-fda-approval-for-uzedys-bipolar-i-expansion/ https://biotechhealthx.com/biotech-news/teva-pharma-teva-wins-fda-approval-for-uzedys-bipolar-i-expansion/" [X Link](https://x.com/BioTechHealthX/status/1978441067830624650) 2025-10-15T12:41Z [---] followers, [---] engagements "$RMD With [--] billion people affected by sleep apnea @Resmed is positioned for explosive growth. See why ResMed is a smart long-term investment. https://biotechhealthx.com/biotech-news/resmed-rmd-dominates-39-7-billion-sleep-health-market/ https://biotechhealthx.com/biotech-news/resmed-rmd-dominates-39-7-billion-sleep-health-market/" [X Link](https://x.com/BioTechHealthX/status/1979794370871386257) 2025-10-19T06:18Z [---] followers, [---] engagements "$DCTH High-margin model and strong cash position set stage for Delcath Systems' rapid commercial growth. Check this out https://biotechhealthx.com/biotech-news/delcath-dcth-revenue-surges-with-87-gross-margin-and-zero-debt-balance-sheet/ https://biotechhealthx.com/biotech-news/delcath-dcth-revenue-surges-with-87-gross-margin-and-zero-debt-balance-sheet/" [X Link](https://x.com/BioTechHealthX/status/1979794493747646468) 2025-10-19T06:19Z [---] followers, [---] engagements "$VNDA Analysts see Vanda Pharmaceuticals' shares surging to $20 from $5.10 as FDA collaboration signals regulatory turnaround. https://biotechhealthx.com/biotech-news/vanda-pharmaceuticals-vnda-targets-300-upside-with-breakthrough-fda-framework-deal/ https://biotechhealthx.com/biotech-news/vanda-pharmaceuticals-vnda-targets-300-upside-with-breakthrough-fda-framework-deal/" [X Link](https://x.com/BioTechHealthX/status/1979794826318278928) 2025-10-19T06:20Z [---] followers, [---] engagements "$DRUG Trading near 86.1% of its 52-week high @brightmindsbio is poised for a major breakout backed by strong fundamentals. https://biotechhealthx.com/biotech-news/bright-minds-biosciences-drug-surges-158-8-in-12-weeks/ https://biotechhealthx.com/biotech-news/bright-minds-biosciences-drug-surges-158-8-in-12-weeks/" [X Link](https://x.com/BioTechHealthX/status/1979794979406086239) 2025-10-19T06:21Z [---] followers, [--] engagements "$RKDA Arcadia Biosciences financial losses are accelerating despite its stock rally. Heres what Wall Street isnt telling you. https://biotechhealthx.com/biotech-news/arcadia-biosciences-rkda-surges-53-but-ebitda-is-still-5-9-million/ https://biotechhealthx.com/biotech-news/arcadia-biosciences-rkda-surges-53-but-ebitda-is-still-5-9-million/" [X Link](https://x.com/BioTechHealthX/status/1979795161954791501) 2025-10-19T06:22Z [---] followers, [--] engagements "$ADXN Strategic partnerships and breakthrough neuroscience pipeline fuel @AddexPharma's massive upside potential. https://biotechhealthx.com/biotech-news/addex-therapeutics-adxn-targets-330-million-milestone-payouts/ https://biotechhealthx.com/biotech-news/addex-therapeutics-adxn-targets-330-million-milestone-payouts/" [X Link](https://x.com/BioTechHealthX/status/1979795311481725232) 2025-10-19T06:22Z [---] followers, [--] engagements "$SLS Late-stage trial momentum of SELLAS Life Sciences Group fuels buyout speculation from Wall Street. Check this out https://biotechhealthx.com/biotech-news/sellas-sls-surged-40-after-hours-on-new-aml-data/ https://biotechhealthx.com/biotech-news/sellas-sls-surged-40-after-hours-on-new-aml-data/" [X Link](https://x.com/BioTechHealthX/status/1979799146459697432) 2025-10-19T06:37Z [---] followers, [---] engagements "$TENX Investors are flocking to Tenax Therapeutics for its rare financial strength and high-growth pipeline. Check this out https://biotechhealthx.com/biotech-news/tenax-tenx-could-be-the-best-funded-microcap-in-biotech/ https://biotechhealthx.com/biotech-news/tenax-tenx-could-be-the-best-funded-microcap-in-biotech/" [X Link](https://x.com/BioTechHealthX/status/1980475305707098379) 2025-10-21T03:24Z [---] followers, [---] engagements "$ADXN @AddexPharma regains global drug rights and targets multi-billion-dollar markets in neurology. Early investors are watching closely. https://biotechhealthx.com/biotech-info/addex-therapeutics-adxn-is-on-the-brink-of-a-breakout/ https://biotechhealthx.com/biotech-info/addex-therapeutics-adxn-is-on-the-brink-of-a-breakout/" [X Link](https://x.com/BioTechHealthX/status/1982345360245969054) 2025-10-26T07:15Z [---] followers, [--] engagements "$NEUP Institutional interest is rising as Neuphoria Therapeutics nears a critical data readout. Click this article to know more https://biotechhealthx.com/biotech-info/hedge-funds-are-quietly-loading-up-on-neuphoria-neup/ https://biotechhealthx.com/biotech-info/hedge-funds-are-quietly-loading-up-on-neuphoria-neup/" [X Link](https://x.com/BioTechHealthX/status/1982345736202363185) 2025-10-26T07:17Z [---] followers, [--] engagements "$ARMP Armata Pharmaceuticals surged 103% after landmark clinical results shocked Wall Street. Read this article to know more information. https://biotechhealthx.com/biotech-news/armata-pharma-armp-skyrockets-103-in-one-day/ https://biotechhealthx.com/biotech-news/armata-pharma-armp-skyrockets-103-in-one-day/" [X Link](https://x.com/BioTechHealthX/status/1982355944937005418) 2025-10-26T07:57Z [---] followers, [--] engagements "$ATNF @180lifesciences now holds over [-----] ETH signaling a bold pivot into crypto wealth. Check this out to know more https://biotechhealthx.com/biotech-news/180-life-sciences-atnf-acquires-82k-eth-after-425m-raise/ https://biotechhealthx.com/biotech-news/180-life-sciences-atnf-acquires-82k-eth-after-425m-raise/" [X Link](https://x.com/BioTechHealthX/status/1982356272164069822) 2025-10-26T07:59Z [---] followers, [--] engagements "$CELZ @creativemedica1's net loss improved to $1.23 million with major upside momentum. Check the full story here. https://biotechhealthx.com/biotech-news/creative-medical-celz-narrows-loss-by-21-and-shares-jump-14/ https://biotechhealthx.com/biotech-news/creative-medical-celz-narrows-loss-by-21-and-shares-jump-14/" [X Link](https://x.com/BioTechHealthX/status/1982360718168256594) 2025-10-26T08:16Z [---] followers, [--] engagements "$KYTX @Kyverna_Tx's leading-edge CAR T pipeline targets massive unmet medical markets. Here's what makes it a smart long-term investment. https://biotechhealthx.com/biotech-news/kyverna-kytx-could-become-the-1st-10b-autoimmune-car-t-company/ https://biotechhealthx.com/biotech-news/kyverna-kytx-could-become-the-1st-10b-autoimmune-car-t-company/" [X Link](https://x.com/BioTechHealthX/status/1982360867644883082) 2025-10-26T08:17Z [---] followers, [---] engagements "$EUDA New market entry in India positions @EUDAHealth Holdings Limited for exponential revenue growth in [----]. Click here to know more https://biotechhealthx.com/biotech-news/euda-health-euda-launches-strategic-india-partnership/ https://biotechhealthx.com/biotech-news/euda-health-euda-launches-strategic-india-partnership/" [X Link](https://x.com/BioTechHealthX/status/1982367469617693144) 2025-10-26T08:43Z [---] followers, [--] engagements "$IMRN @ImmuronLtd boosts R&D funding to expand its oral immunotherapy pipeline and strengthen IMRN stocks biotech outlook in [----]. https://biotechhealthx.com/biotech-news/immuron-imrn-raises-8-5m-for-biotech-expansion/ https://biotechhealthx.com/biotech-news/immuron-imrn-raises-8-5m-for-biotech-expansion/" [X Link](https://x.com/BioTechHealthX/status/1986487918777803264) 2025-11-06T17:36Z [---] followers, [--] engagements "$MTSR Two pharma titans @pfizer and @teamnovonordisk fight for control of @MetseraInc's next-gen obesity pipeline in record-setting biotech battle. https://biotechhealthx.com/biotech-info/pfizer-vs-novo-nordisk-the-10b-war-over-metsera-mtsr/ https://biotechhealthx.com/biotech-info/pfizer-vs-novo-nordisk-the-10b-war-over-metsera-mtsr/" [X Link](https://x.com/BioTechHealthX/status/1986488159887380799) 2025-11-06T17:37Z [---] followers, [---] engagements "$GKOS Brown Capitals $34.6M sale didnt shake confidence. @GlaukosCorp's glaucoma implants 22% revenue growth and $475M sales forecast fuel optimism. https://biotechhealthx.com/biotech-news/why-glaukos-gkos-could-surge-30-in-2025/ https://biotechhealthx.com/biotech-news/why-glaukos-gkos-could-surge-30-in-2025/" [X Link](https://x.com/BioTechHealthX/status/1986488542332334262) 2025-11-06T17:39Z [---] followers, [--] engagements "$INDV @Indivior boosts full-year outlook following strong execution in OUD platform; can INDV double Click here to know more https://biotechhealthx.com/biotech-news/why-indivior-indv-just-raised-2025-revenue-guidance-to-1-18-1-22b/ https://biotechhealthx.com/biotech-news/why-indivior-indv-just-raised-2025-revenue-guidance-to-1-18-1-22b/" [X Link](https://x.com/BioTechHealthX/status/1986495293286912274) 2025-11-06T18:05Z [---] followers, [--] engagements "$VIVS VivoSim Labs jumps as the company reports key simulation-model advancement and eyes non-animal biotech market growth. https://biotechhealthx.com/biotech-news/vivosim-labs-vivs-surges-19-8-after-clinical-trial-breakthrough/ https://biotechhealthx.com/biotech-news/vivosim-labs-vivs-surges-19-8-after-clinical-trial-breakthrough/" [X Link](https://x.com/BioTechHealthX/status/1986495429379563589) 2025-11-06T18:06Z [---] followers, [--] engagements "$TECX Wall Street turns bullish on Tectonic Therapeutic after strong TX45 heart failure results. Check this article to learn more https://biotechhealthx.com/biotech-news/tectonic-therapeutic-tecx-gets-bullish-boost-analysts-predict-330-rally/ https://biotechhealthx.com/biotech-news/tectonic-therapeutic-tecx-gets-bullish-boost-analysts-predict-330-rally/" [X Link](https://x.com/BioTechHealthX/status/1986495620367216768) 2025-11-06T18:07Z [---] followers, [---] engagements "$GH DCF model shows @GuardantHealth trading 61.9% below fair value despite massive [----] rally. Read this article to know more. https://biotechhealthx.com/biotech-news/why-analysts-see-guardant-health-gh-rallying-to-249/ https://biotechhealthx.com/biotech-news/why-analysts-see-guardant-health-gh-rallying-to-249/" [X Link](https://x.com/BioTechHealthX/status/1986496827403943973) 2025-11-06T18:12Z [---] followers, [--] engagements "$INVA Innoviva posts revenue of $107.8M and net income of $89.9 million in Q3 [----] marking its strongest quarter ever and a $125M buyback launch. https://biotechhealthx.com/biotech-news/innoviva-inva-surges-after-record-q3-2025-earnings/ https://biotechhealthx.com/biotech-news/innoviva-inva-surges-after-record-q3-2025-earnings/" [X Link](https://x.com/BioTechHealthX/status/1987076089022382174) 2025-11-08T08:33Z [---] followers, [---] engagements "$AFJK Aimei Health Technology trades at $11.33 with a 1-year high of $11.49. Could its $69M SPAC war chest fuel a surprise rally https://biotechhealthx.com/biotech-news/can-aimei-health-afjk-defy-weiss-ratings-bearish-call/ https://biotechhealthx.com/biotech-news/can-aimei-health-afjk-defy-weiss-ratings-bearish-call/" [X Link](https://x.com/BioTechHealthX/status/1987076289375969391) 2025-11-08T08:34Z [---] followers, [--] engagements "$IOVA Trading at just $2.31 with a fair value of $8.X @IovanceBio offers 71% upside driven by FDA approval growing sales & a massive oncology pipeline. https://biotechhealthx.com/biotech-news/iovance-bio-iova-the-most-undervalued-cancer-stock-in-the-market/ https://biotechhealthx.com/biotech-news/iovance-bio-iova-the-most-undervalued-cancer-stock-in-the-market/" [X Link](https://x.com/BioTechHealthX/status/1987076462432952807) 2025-11-08T08:35Z [---] followers, [---] engagements "$TECX Tectonic Therapeutics posts strong Phase 1b results in PH-HFrEF and reports $268.4M in cash giving a solid runway through [----]. https://biotechhealthx.com/biotech-news/tectonic-therapeutics-tecx-surges-on-positive-tx45-trial-data/ https://biotechhealthx.com/biotech-news/tectonic-therapeutics-tecx-surges-on-positive-tx45-trial-data/" [X Link](https://x.com/BioTechHealthX/status/1987076609648828603) 2025-11-08T08:35Z [---] followers, [---] engagements "$URGN Phase [--] UTOPIA trial results boost confidence in UGN-103 pushing @UroGenPharma closer to a [----] NDA submission and potential market expansion. https://biotechhealthx.com/biotech-info/urogen-urgns-ugn-103-delivers-77-8-success-rate/ https://biotechhealthx.com/biotech-info/urogen-urgns-ugn-103-delivers-77-8-success-rate/" [X Link](https://x.com/BioTechHealthX/status/1987185905753596331) 2025-11-08T15:50Z [---] followers, [--] engagements "$PEN Penumbra jumps after Q3 [----] earnings beat; $355 M revenue and $1.17 EPS spark stronger [----] forecasts. Click here to learn more https://biotechhealthx.com/biotech-news/penumbra-pen-reports-355m-revenue-29-eps-beat/ https://biotechhealthx.com/biotech-news/penumbra-pen-reports-355m-revenue-29-eps-beat/" [X Link](https://x.com/BioTechHealthX/status/1987186037526003793) 2025-11-08T15:50Z [---] followers, [--] engagements "$NHTC Natural Health Trends posts Q3 [----] revenue of just $9.5 M down 11% year-over-year as restructuring kicks in. Click here to know more https://biotechhealthx.com/biotech-news/natural-health-trends-nhtc-q3-revenue-falls-11-to-9-5-m/ https://biotechhealthx.com/biotech-news/natural-health-trends-nhtc-q3-revenue-falls-11-to-9-5-m/" [X Link](https://x.com/BioTechHealthX/status/1987413126246244519) 2025-11-09T06:53Z [---] followers, [--] engagements "$ACOG @AlphaCognition1 is positioning itself as a leader in neurodegenerative treatment innovation with ZUNVEYL. Read this article to know more. https://biotechhealthx.com/biotech-news/why-alpha-cognition-acog-could-be-the-next-big-alzheimers-breakthrough-stock/ https://biotechhealthx.com/biotech-news/why-alpha-cognition-acog-could-be-the-next-big-alzheimers-breakthrough-stock/" [X Link](https://x.com/BioTechHealthX/status/1987425228591595524) 2025-11-09T07:41Z [---] followers, [---] engagements "$CRMD CorMedix Inc. reports record Q3 [----] profit of $108.6M and raises full-year revenue guidance to $410M investors take notice. https://biotechhealthx.com/biotech-news/cormedix-crmd-surges-after-posting-108-6m-net-income-in-q3-2025/ https://biotechhealthx.com/biotech-news/cormedix-crmd-surges-after-posting-108-6m-net-income-in-q3-2025/" [X Link](https://x.com/BioTechHealthX/status/1988657406746951759) 2025-11-12T17:17Z [---] followers, [---] engagements "$VKTX Leaders in the obesity treatment space estimate a $100 B market by [----] Viking Therapeutics is positioned to capture major share. https://biotechhealthx.com/biotech-news/why-viking-therapeutics-vktx-could-dominate-the-100b-obesity-drug-market-by-2030/ https://biotechhealthx.com/biotech-news/why-viking-therapeutics-vktx-could-dominate-the-100b-obesity-drug-market-by-2030/" [X Link](https://x.com/BioTechHealthX/status/1988657651560141145) 2025-11-12T17:18Z [---] followers, [---] engagements "$ABEO Abeona cuts net loss from $30.3 M to $5.2 M and expands rare-disease network as ZEVASKYN demand surges ahead of launch. https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-slashes-quarterly-loss-by-83/ https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-slashes-quarterly-loss-by-83/" [X Link](https://x.com/BioTechHealthX/status/1988657847572525224) 2025-11-12T17:19Z [---] followers, [--] engagements "$TRVI Trevi Therapeutics (TRVI) shocks investors with a massive $194.9 million cash and securities balance securing a runway into [----] while advancing Haduvio for chronic cough in IPF and RCC. Learn why analysts expect major upside. https://biotechhealthx.com/biotech-news/trevi-therapeutics-trvi-surges-as-cash-runway-extends-to-2028-after-reporting-194-9m-assets/ https://biotechhealthx.com/biotech-news/trevi-therapeutics-trvi-surges-as-cash-runway-extends-to-2028-after-reporting-194-9m-assets/" [X Link](https://x.com/BioTechHealthX/status/1989953870920126802) 2025-11-16T07:09Z [---] followers, [---] engagements "$CDTX Shares of @CidaraThera (NASDAQ:CDTX) doubled to $217.89 after Merck offered a 108.9% premium to buy the company. With the FDA granting breakthrough designation to CD388 and a 6000-patient Phase [--] trial underway this could be the biotech breakout of the decade. https://biotechhealthx.com/biotech-news/cidara-therapeutics-cdtx-skyrockets-108-9-as-merck-acquisition-hits-221-50-per-share/ https://biotechhealthx.com/biotech-news/cidara-therapeutics-cdtx-skyrockets-108-9-as-merck-acquisition-hits-221-50-per-share/" [X Link](https://x.com/BioTechHealthX/status/1989954029049581879) 2025-11-16T07:09Z [---] followers, [--] engagements "$MRSN Mersana Therapeutics (MRSN) announces a blockbuster merger worth up to $285M including $25 cash per share and $30.25 in CVRs tied to Emi-Le milestones. Heres why the ADC developer is suddenly a biotech standout. https://biotechhealthx.com/biotech-news/mersana-therapeutics-mrsn-surges-after-285m-acquisition-deal-with-day-one-biopharmaceuticals/ https://biotechhealthx.com/biotech-news/mersana-therapeutics-mrsn-surges-after-285m-acquisition-deal-with-day-one-biopharmaceuticals/" [X Link](https://x.com/BioTechHealthX/status/1989954188433113112) 2025-11-16T07:10Z [---] followers, [--] engagements "$KRRO @KorroBio (KRRO) confirmed functional M-AAT protein production in AATD patients in its Phase 1/2a REWRITE trial. With RNA editing validated in humans regulatory breakthroughs and GalNAc programs advancing into [--------] KRRO becomes one of the hottest genetic medicine stocks to watch. https://biotechhealthx.com/biotech-news/korro-bio-krro-surges-after-human-rna-editing-success-in-aatd-trial/ https://biotechhealthx.com/biotech-news/korro-bio-krro-surges-after-human-rna-editing-success-in-aatd-trial/" [X Link](https://x.com/BioTechHealthX/status/1989958117887754568) 2025-11-16T07:26Z [---] followers, [---] engagements "$TWST @TwistBioscience ended fiscal [----] with $232.4M in cash and short-term investments despite heavy operating expenses of $327.3M. As the company invests in MRD Express protein solutions and AI discovery tools investors question whether future dilution or debt will be needed to sustain growth. https://biotechhealthx.com/biotech-news/twist-bioscience-twst-cash-position-hits-232-4m-is-it-enough-to-fund-2026-expansion/ https://biotechhealthx.com/biotech-news/twist-bioscience-twst-cash-position-hits-232-4m-is-it-enough-to-fund-2026-expansion/" [X Link](https://x.com/BioTechHealthX/status/1989958563507421514) 2025-11-16T07:27Z [---] followers, [---] engagements "$OSCR @OscarHealth (NASDAQ:OSCR) projects strong revenue growth through [----] driven by ACA expansion AI-driven plans and its +Oscar full-stack platform. With an earnings swing from $161.2M to +$245.4M OSCR could be one of the most undervalued tech-enabled insurers today. https://biotechhealthx.com/biotech-news/why-analysts-believe-oscar-health-oscr-could-become-a-12b-plus-digital-insurance-powerhouse/ https://biotechhealthx.com/biotech-news/why-analysts-believe-oscar-health-oscr-could-become-a-12b-plus-digital-insurance-powerhouse/" [X Link](https://x.com/BioTechHealthX/status/1990084109633458636) 2025-11-16T15:46Z [---] followers, [---] engagements "$YDES YD Bio Limited (YDES) became a Nasdaq-listed biotech after completing a major merger and securing $13.2M in PIPE financing. With DNA methylation cancer detection for pancreatic and breast cancer and exosome-based eye therapies in development investors are asking whether YDES is positioned for massive growth in [----] and beyond. https://biotechhealthx.com/biotech-news/yd-bio-ydes-surges-after-13-2m-financing/ https://biotechhealthx.com/biotech-news/yd-bio-ydes-surges-after-13-2m-financing/" [X Link](https://x.com/BioTechHealthX/status/1990084263589658704) 2025-11-16T15:47Z [---] followers, [--] engagements "$APUS Following its ai Futures Lab expansion and continued progress of Apitox in late-stage development @apimedsai2 appears significantly undervalued relative to its innovative platform. Discover why APUS may offer substantial upside as investors search for the next non-opioid breakthrough. https://biotechhealthx.com/biotech-news/is-apimeds-apus-the-most-undervalued-small-cap-biotech/ https://biotechhealthx.com/biotech-news/is-apimeds-apus-the-most-undervalued-small-cap-biotech/" [X Link](https://x.com/BioTechHealthX/status/1990084550912032923) 2025-11-16T15:48Z [---] followers, [--] engagements "$INDP INDP stock gains attention as @indaptus secures $2.3M through its ATM facility completes its Safety Lead-In cohort and posts improving financial trendspositioning the company for a pivotal clinical expansion heading into [----]. https://biotechhealthx.com/biotech-news/why-indaptus-indp-could-be-a-sleeper-biotech-winner-after-2-3m-financing-boost-and-phase-1-progress/ https://biotechhealthx.com/biotech-news/why-indaptus-indp-could-be-a-sleeper-biotech-winner-after-2-3m-financing-boost-and-phase-1-progress/" [X Link](https://x.com/BioTechHealthX/status/1990632352859771137) 2025-11-18T04:05Z [---] followers, [--] engagements "$CYPH Cypherpunk Technologies (CYPH) surged 284% in just one week after rebranding from Leap Therapeutics and launching a bold $58.9 million Zcash treasury strategy. Learn why investors believe CYPHs digital-asset pivot could unlock massive upside despite a 37x price-to-book ratio. https://biotechhealthx.com/biotech-news/cypherpunk-technologies-cyph-skyrockets-284-in-one-week-after-58-9m-crypto-pivot/ https://twitter.com/i/web/status/1990632661275324644 https://biotechhealthx.com/biotech-news/cypherpunk-technologies-cyph-skyrockets-284-in-one-week-after-58-9m-crypto-pivot/" [X Link](https://x.com/BioTechHealthX/status/1990632661275324644) 2025-11-18T04:06Z [---] followers, [---] engagements "$RYTM Rhythm Pharmaceuticals Inc. (RYTM) faces a three-month FDA review extension for IMCIVREE in acquired hypothalamic obesity moving the PDUFA date to March [--] [----]. With Q3 revenue rising to $51.3M from $33.25M YoY investors now wonder whether the delay signals a massive upside opportunity for this rare-disease leader. https://biotechhealthx.com/biotech-news/rhythm-pharma-rytm-surges-as-fda-extends-review-for-imcivree/ https://biotechhealthx.com/biotech-news/rhythm-pharma-rytm-surges-as-fda-extends-review-for-imcivree/" [X Link](https://x.com/BioTechHealthX/status/1990640062632178133) 2025-11-18T04:35Z [---] followers, [---] engagements "$BDTX Black Diamond Therapeutics (BDTX) soared 115.9% year-to-date and hit a new 52-week high at $4.65. With four straight earnings beats and a Zacks Rank #2 Buy rating analysts project $0.46 EPS on $70M revenue. See why BDTX may still be massively undervalued. https://biotechhealthx.com/biotech-news/black-diamond-therapeutics-bdtx-surges-115-9-ytd/ https://biotechhealthx.com/biotech-news/black-diamond-therapeutics-bdtx-surges-115-9-ytd/" [X Link](https://x.com/BioTechHealthX/status/1990640236431618117) 2025-11-18T04:36Z [---] followers, [---] engagements "$AVTX Avalo Therapeutics Inc. (AVTX) received a reaffirmed $48 price target from Piper Sandler implying a stunning 167.86% upside. With AVTX-009 advancing in Phase [--] hidradenitis suppurativa trials and new leadership strengthening execution analysts say this immunology stock may be one of biotechs biggest long-term winners. https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-set-for-167-86-surge-piper-sandler-reaffirms-massive-48-price-target/ https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-set-for-167-86-surge-piper-sandler-reaffirms-massive-48-price-target/" [X Link](https://x.com/BioTechHealthX/status/1990640408117064027) 2025-11-18T04:37Z [---] followers, [---] engagements "$FULC FULC stock gains momentum as pociredir demonstrates dose-dependent HbF induction and no treatment-related SAEs. With $200.6M cash and multiple IND programs planned Fulcrum Therapeutics (NASDAQ: FULC) positions itself as a top genetic-disease biotech to watch in [----]. https://biotechhealthx.com/biotech-news/is-fulcrum-therapeutics-fulc-the-next-rare-disease-winner-new-data-says-yes/ https://biotechhealthx.com/biotech-news/is-fulcrum-therapeutics-fulc-the-next-rare-disease-winner-new-data-says-yes/" [X Link](https://x.com/BioTechHealthX/status/1990640570167857340) 2025-11-18T04:37Z [---] followers, [---] engagements "$OLMA Olema Pharmaceuticals (NASDAQ:OLMA) gained massive investor attention after Roche announced positive Phase [--] results for giredestrant validating the same drug class as Olemas lead therapy palazestrant. Learn why this breakthrough could dramatically increase OLMAs probability of trial success and long-term valuation" [X Link](https://x.com/BioTechHealthX/status/1991020586689265869) 2025-11-19T05:47Z [---] followers, [--] engagements "$KZIA Kazia Therapeutics (NASDAQ:KZIA) now faces imminent delisting after failing to regain NASDAQ compliance by Nov. [--] [----]. With a market cap of only $10.47M declining revenues negative equity and strong sell technical signals KZIA investors are bracing for a possible suspension. https://biotechhealthx.com/biotech-news/kazia-therapeutics-kzia-faces-nasdaq-delisting-after-missing-compliance-deadline-is-this-the-end/ https://biotechhealthx.com/biotech-news/kazia-therapeutics-kzia-faces-nasdaq-delisting-after-missing-compliance-deadline-is-this-the-end/" [X Link](https://x.com/BioTechHealthX/status/1991020898242211885) 2025-11-19T05:49Z [---] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@BioTechHealthX BioTech Health X
BioTech Health X posts on X about health, nasdaq, stocks, strong the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] +181%
- [--] Month [-----] -4.80%
- [--] Months [------] +224%
- [--] Year [------] +6,857%
Mentions: [--] #
- [--] Month [--] -52%
- [--] Months [---] +390%
- [--] Year [---] +8,775%
Followers: [---] #
- [--] Week [---] +2.50%
- [--] Month [---] +3.80%
- [--] Months [---] +23%
- [--] Year [---] +46%
CreatorRank: [---------] #
Social Influence
Social category influence stocks finance exchanges cryptocurrencies countries technology brands automotive brands currencies travel destinations champions league
Social topic influence health, nasdaq #741, stocks, strong, wall street, target, future, longterm, breakout, market cap #941
Top accounts mentioned or mentioned by @jnjnews @novonordisk @unitedhealthgrp @4dmolecular @transmedics @crinetics @sellaslife @oscarhealth @pfizer @novavax @immunitybio @tgtherapeutics @axsome @brightmindsbio @elilillyandco @axogen @krystalbiotech @urogenpharma @teamnovonordisk @admabiologics
Top assets mentioned Novo-Nordisk (NVO) Johnson & Johnson (JNJ) UnitedHealth Group (UNH) Candel Therapeutics, Inc. (CADL) Molina Healthcare, Inc. (MOH) Cadrenal Therapeutics, Inc. (CVKD) Intuitive Surgical, Inc. (ISRG) Axsome Therapeutics, Inc (AXSM) 4D Molecular Therapeutics Inc. (FDMT) Ocular Therapeutix, Inc. (OCUL) TransMedics Group, Inc. Common Stock (TMDX) Crinetics Pharmaceuticals, Inc. (CRNX) Boston Scientific Corporation (BSX) Basilisk (BSX) Oscar Health, Inc. (OSCR) Novavax Inc (NVAX) ImmunityBio, Inc. Common Stock (IBRX) TG Therapeutics, Inc. (TGTX) Elevance Health Inc (ELV) Kyverna Therapeutics, Inc. (KYTX) Viking Therapeutics, Inc (VKTX) Greenwich LifeSciences, Inc. (GLSI) Prelude Therapeutics Inc. (PRLD) Janux Therapeutics, Inc. (JANX) BEAM (BEAM) Hims & Hers Health, Inc. (HIMS) Eli Lilly and Company (LLY) Krystal Biotech, Inc. Common Stock (KRYS) ADMA Biologics, Inc. (ADMA) Kymera Therapeutics, Inc. (KYMR) Emergent Biosolutions, Inc. (EBS) Metsera, Inc. (MTSR) Agios Pharmaceuticals, Inc. (AGIO)
Top Social Posts
Top posts by engagements in the last [--] hours
"Biotech Stocks Soaring Today $JANX 187% $VJTX 63% $HIMS 29% $BEAM 33% $OAC 30% $AHCO 30%"
X Link 2024-02-27T15:41Z [---] followers, [---] engagements
".@EliLillyandCo announced at the #INGlobalSummit w/ @GovHolcomb a $5.3B investment into the company's Lebanon Indiana production facility set to meet the increasing demand for its diabetes and weight loss drugs Mounjaro and Zepbound. $LLY https://biotechhealthx.com/biotech-news/eli-lilly-announces-historic-5-3-billion-investment-to-expand-indiana-manufacturing-for-diabetes-and-weight-loss-drugs/ https://biotechhealthx.com/biotech-news/eli-lilly-announces-historic-5-3-billion-investment-to-expand-indiana-manufacturing-for-diabetes-and-weight-loss-drugs/"
X Link 2024-05-24T17:21Z [---] followers, [--] engagements
"New @NovoNordiskUS Phase [--] FLOW study published in @NEJM highlights Ozempic's significant benefits in reducing risk of kidney disease events cardiovascular issues & mortality in patients with type [--] diabetes and chronic kidney disease. $NVO https://biotechhealthx.com/biotech-news/ozempic-shows-lower-risk-of-kidney-and-heart-complications-in-diabetic-patients/ https://biotechhealthx.com/biotech-news/ozempic-shows-lower-risk-of-kidney-and-heart-complications-in-diabetic-patients/"
X Link 2024-05-24T18:21Z [---] followers, [---] engagements
"$TBPH This cash-rich debt-free company is advancing a rare disease blockbuster while pulling in strong COPD revenue. Check Theravance Biopharma. https://biotechhealthx.com/biotech-news/biotech-bargain-alert-theravance-biopharma-tbph-may-offer-triple-digit-upside-in-2025/ https://biotechhealthx.com/biotech-news/biotech-bargain-alert-theravance-biopharma-tbph-may-offer-triple-digit-upside-in-2025/"
X Link 2025-07-04T17:53Z [---] followers, [--] engagements
"$PTHS @PelthosT just closed a strategic merger & is launching its first drug. With a clean balance sheet and big vision investors are taking notice. https://biotechhealthx.com/biotech-news/pelthos-therapeutics-pths-zero-debt-50m-in-cash-and-an-fda-greenlight-whats-not-to-love/ https://biotechhealthx.com/biotech-news/pelthos-therapeutics-pths-zero-debt-50m-in-cash-and-an-fda-greenlight-whats-not-to-love/"
X Link 2025-07-04T17:54Z [---] followers, [--] engagements
"$GSK After spinning off Haleon & supercharging its pipeline GlaxoSmithKline has outpaced the medical sector by 16% YTD. Analysts are bullish. https://biotechhealthx.com/biotech-news/glaxosmithkline-gsks-reinvention-is-complete-will-this-drug-giant-deliver-50-upside-in-2025/ https://biotechhealthx.com/biotech-news/glaxosmithkline-gsks-reinvention-is-complete-will-this-drug-giant-deliver-50-upside-in-2025/"
X Link 2025-07-04T17:55Z [---] followers, [--] engagements
"$AIM Backed by a fresh patent stock split & NYSE compliance extension AIM Immunotech is ready to rebound hard in [----]. See why this stock is a smart pick https://biotechhealthx.com/biotech-news/from-penny-stock-to-powerhouse-aim-immunotech-aims-comeback-could-be-epic/ https://biotechhealthx.com/biotech-news/from-penny-stock-to-powerhouse-aim-immunotech-aims-comeback-could-be-epic/"
X Link 2025-07-05T03:06Z [---] followers, [--] engagements
"$AMGN A deep pipeline blockbuster drugs & $27B acquisitions @Amgen is set to dominate in obesity oncology & rare diseases. Dont miss the chance https://biotechhealthx.com/biotech-news/buy-the-biotech-blue-chip-before-the-surge-why-amgen-amgn-could-soar-in-2025/ https://biotechhealthx.com/biotech-news/buy-the-biotech-blue-chip-before-the-surge-why-amgen-amgn-could-soar-in-2025/"
X Link 2025-07-06T16:35Z [---] followers, [--] engagements
"$MOH Molina Healthcare's shares skidded to $262 even after crushing Q1 earnings. See why investors are calling this the best bargain in healthcare. https://biotechhealthx.com/biotech-news/buy-the-dip-molina-healthcare-moh-just-hit-a-52-week-low-and-the-upside-is-stunning/ https://biotechhealthx.com/biotech-news/buy-the-dip-molina-healthcare-moh-just-hit-a-52-week-low-and-the-upside-is-stunning/"
X Link 2025-07-06T16:36Z [---] followers, [--] engagements
"$JNJ Stable cash-rich and innovation-focused @JNJ checks all the boxesso why isnt it in Buffetts portfolio And should it be in yours https://biotechhealthx.com/biotech-news/warren-buffett-missed-this-one-why-johnson-johnson-jnj-may-be-the-best-buy-he-never-made/ https://biotechhealthx.com/biotech-news/warren-buffett-missed-this-one-why-johnson-johnson-jnj-may-be-the-best-buy-he-never-made/"
X Link 2025-07-06T16:37Z [---] followers, [--] engagements
"$ABEO After cutting losses & scoring a huge gene therapy approval @AbeonaBio is seen to be profitable in [----]. See why Wall Street is turning bullish. https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-s-set-to-breakeven-and-analysts-say-its-just-the-beginning/ https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-s-set-to-breakeven-and-analysts-say-its-just-the-beginning/"
X Link 2025-07-19T03:38Z [---] followers, [--] engagements
"$AXGN With global expansion FDA approvals & high-margin growth @axogen is rewriting the rules of nerve regeneration. Check this out. https://biotechhealthx.com/biotech-news/axogen-axgn-is-reinventing-nerve-repair-and-it-could-make-early-investors-rich/ https://biotechhealthx.com/biotech-news/axogen-axgn-is-reinventing-nerve-repair-and-it-could-make-early-investors-rich/"
X Link 2025-07-19T03:39Z [---] followers, [---] engagements
"$HNST The Honest Company is turning heads with [--] straight quarters of positive EBITDA zero debt and explosive retail expansion potential. https://biotechhealthx.com/biotech-news/the-honest-company-hnst-could-be-wall-streets-most-underrated-clean-brand-stock-right-now/ https://biotechhealthx.com/biotech-news/the-honest-company-hnst-could-be-wall-streets-most-underrated-clean-brand-stock-right-now/"
X Link 2025-07-20T17:05Z [---] followers, [---] engagements
"$REPL Analysts are piling on @Replimune with bullish price targets ahead of RP1s FDA decision. See why REPL could surge in [----]. https://biotechhealthx.com/biotech-news/wall-street-sees-75-upside-is-replimune-repl-the-best-biotech-stock-to-buy-now/ https://biotechhealthx.com/biotech-news/wall-street-sees-75-upside-is-replimune-repl-the-best-biotech-stock-to-buy-now/"
X Link 2025-07-21T11:06Z [---] followers, [----] engagements
"$TMDX Just like @Tesla reimagined vehicles @Transmedics is redefining organ transport. See how TMDXs OCS platform is turning heads on Wall Street. https://biotechhealthx.com/biotech-news/transmedics-tmdx-could-be-the-tesla-of-transplants-heres-why-investors-are-paying-attention/ https://biotechhealthx.com/biotech-news/transmedics-tmdx-could-be-the-tesla-of-transplants-heres-why-investors-are-paying-attention/"
X Link 2025-07-21T11:07Z [---] followers, [----] engagements
"$MEDP Medpace shocked Wall Street with a record-breaking earnings beat & stock surge. This clinical trial powerhouse could be your next big winner. https://biotechhealthx.com/biotech-news/medpace-medp-just-soared-50-is-this-the-most-underrated-biotech-play-of-2025/ https://biotechhealthx.com/biotech-news/medpace-medp-just-soared-50-is-this-the-most-underrated-biotech-play-of-2025/"
X Link 2025-07-22T16:31Z [---] followers, [--] engagements
"$MCRB Investors are eyeing Seres Therapeutics after its Vowst approval and SER-155 breakthrough. This could be the best kept secret in healthcare. https://biotechhealthx.com/biotech-news/seres-therapeutics-mcrb-the-100m-microbiome-gem-flying-under-wall-streets-radar/ https://biotechhealthx.com/biotech-news/seres-therapeutics-mcrb-the-100m-microbiome-gem-flying-under-wall-streets-radar/"
X Link 2025-07-22T16:33Z [---] followers, [---] engagements
"$KRYS With the first redosable gene therapy approved by the FDA & a pipeline expanding into eye diseases @KrystalBiotech could breakout anytime https://biotechhealthx.com/biotech-news/krystal-biotech-krys-just-changed-gene-therapy-forever-smart-investors-are-paying-attention/ https://biotechhealthx.com/biotech-news/krystal-biotech-krys-just-changed-gene-therapy-forever-smart-investors-are-paying-attention/"
X Link 2025-07-22T16:33Z [---] followers, [---] engagements
"$TMO Whether its research labs or vaccine production @thermofisher has its fingerprints on every major scientific innovation today. https://biotechhealthx.com/biotech-news/thermo-fisher-tmo-is-everywhere-and-thats-exactly-why-its-winning/ https://biotechhealthx.com/biotech-news/thermo-fisher-tmo-is-everywhere-and-thats-exactly-why-its-winning/"
X Link 2025-07-23T14:04Z [---] followers, [--] engagements
"$MTVA With a bold rebrand and two clinical-stage assets MetaVia is chasing GLP-1 giants & eyeing FDA milestones. Investors should take notice now. https://biotechhealthx.com/biotech-news/from-neurobo-to-metavia-mtva-this-biotech-just-went-all-in-on-obesity-and-liver-disease/ https://biotechhealthx.com/biotech-news/from-neurobo-to-metavia-mtva-this-biotech-just-went-all-in-on-obesity-and-liver-disease/"
X Link 2025-07-23T14:05Z [---] followers, [---] engagements
"$APLS With SYFOVRE sales surging & EMPAVELI awaiting FDA approval @ApellisPharma could explode in [----]. See why it could be the next breakout star. https://biotechhealthx.com/biotech-news/fda-decision-incoming-apellis-pharmaceuticals-apls-could-be-the-next-10x-biotech-stock/ https://biotechhealthx.com/biotech-news/fda-decision-incoming-apellis-pharmaceuticals-apls-could-be-the-next-10x-biotech-stock/"
X Link 2025-07-29T00:57Z [---] followers, [---] engagements
"$URGN @UroGenPharma cancer therapies are shaking up uro-oncology. See why analysts predict massive growth & why investors are piling into URGN stock. https://biotechhealthx.com/biotech-news/wall-street-is-going-crazy-over-urogen-pharma-urgn-heres-why-it-could-be-a-2025-winner/ https://biotechhealthx.com/biotech-news/wall-street-is-going-crazy-over-urogen-pharma-urgn-heres-why-it-could-be-a-2025-winner/"
X Link 2025-07-29T00:58Z [---] followers, [---] engagements
"$QNTM With a game-changing MS therapy a booming consumer product and insider confidence Quantum Biopharma could explode in [----]. https://biotechhealthx.com/biotech-news/wall-street-doesnt-want-you-to-see-this-stock-quantum-qntm-could-be-the-next-jackpot/ https://biotechhealthx.com/biotech-news/wall-street-doesnt-want-you-to-see-this-stock-quantum-qntm-could-be-the-next-jackpot/"
X Link 2025-08-01T18:37Z [---] followers, [--] engagements
"$PHLT Performant Healthcare exploded as Machinify announced its acquisition. Heres how Performant Healthcare became a 3month success story. https://biotechhealthx.com/biotech-news/performant-healthcare-phlt-gets-670m-buyout-could-this-be-the-smartest-trade-of-2025/ https://biotechhealthx.com/biotech-news/performant-healthcare-phlt-gets-670m-buyout-could-this-be-the-smartest-trade-of-2025/"
X Link 2025-08-01T18:37Z [---] followers, [--] engagements
"$NVO @teamnovonordisk shares have wiped out gains since Wegovys launch. This crash could be the perfect chance to buy before the next massive rally. https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-is-this-the-biggest-buying-opportunity-of-2025/ https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-is-this-the-biggest-buying-opportunity-of-2025/"
X Link 2025-08-04T01:37Z [---] followers, [---] engagements
"$ADMA Analysts project billions in peak sales for ASCENIV as @AdmaBiologics scales production. Learn why Wall Street is going all in. https://biotechhealthx.com/biotech-news/adma-biologics-adma-could-be-the-next-billion-dollar-biotech-superstar/ https://biotechhealthx.com/biotech-news/adma-biologics-adma-could-be-the-next-billion-dollar-biotech-superstar/"
X Link 2025-08-04T01:38Z [---] followers, [---] engagements
"$JNJ Institutions are snapping up @JNJNews shares as analysts predict strong gains. Learn why this Dividend King may be the ultimate [----] stock. https://biotechhealthx.com/biotech-news/the-secret-wall-street-play-why-big-money-is-buying-johnson-johnson-jnj/ https://biotechhealthx.com/biotech-news/the-secret-wall-street-play-why-big-money-is-buying-johnson-johnson-jnj/"
X Link 2025-08-04T01:39Z [---] followers, [--] engagements
"$TNXP With positive Phase [--] trial data and a crucial PDUFA date coming soon Tonix Pharmaceuticals may be on the verge of a massive breakout. https://biotechhealthx.com/biotech-news/fda-approval-could-send-tonix-pharmaceuticals-tnxp-soaring-dont-miss-out/ https://biotechhealthx.com/biotech-news/fda-approval-could-send-tonix-pharmaceuticals-tnxp-soaring-dont-miss-out/"
X Link 2025-08-04T01:39Z [---] followers, [----] engagements
"$FULC Pociredirs strong efficacy clean safety and massive potential market make Fulcrum one of the most exciting biotech plays right now. https://biotechhealthx.com/biotech-news/fulcrum-therapeutics-fulcs-stunning-trial-results-could-make-it-the-next-biotech-breakout/ https://biotechhealthx.com/biotech-news/fulcrum-therapeutics-fulcs-stunning-trial-results-could-make-it-the-next-biotech-breakout/"
X Link 2025-08-04T02:51Z [---] followers, [---] engagements
"$HIMS Analysts are betting big on @himsandher as it targets $1.3B in EBITDA. See the growth blueprint behind this potential 10-bagger. https://biotechhealthx.com/biotech-news/hims-hers-hims-could-10x-by-2030-the-6-5-billion-bull-case-you-need-to-see/ https://biotechhealthx.com/biotech-news/hims-hers-hims-could-10x-by-2030-the-6-5-billion-bull-case-you-need-to-see/"
X Link 2025-08-05T15:23Z [---] followers, [--] engagements
"$QBTS With a new AI toolkit and real-world quantum applications @dwavequantum is positioning itself to dominate a trillion-dollar future. Learn more here https://biotechhealthx.com/biotech-news/d-wave-qbts-just-changed-the-game-for-ai-and-their-stock-may-be-the-next-10x-winner/ https://biotechhealthx.com/biotech-news/d-wave-qbts-just-changed-the-game-for-ai-and-their-stock-may-be-the-next-10x-winner/"
X Link 2025-08-05T15:24Z [---] followers, [--] engagements
"$NTRB @nutriband is closer than ever to changing the opioid industry. FDA filing is next and early investors are watching. https://biotechhealthx.com/biotech-news/nutriband-ntrb-the-1-biotech-that-could-10x-by-solving-americas-opioid-problem/ https://biotechhealthx.com/biotech-news/nutriband-ntrb-the-1-biotech-that-could-10x-by-solving-americas-opioid-problem/"
X Link 2025-08-05T15:25Z [---] followers, [---] engagements
"$KYMR With KT-621 showing Dupixent-like results and a pipeline full of first-in-class therapies @kymera could be the biotech dream stock. https://biotechhealthx.com/biotech-news/2-3-billion-potential-why-kymera-therapeutics-kymr-might-be-the-biggest-sleeper-stock-in-biotech/ https://biotechhealthx.com/biotech-news/2-3-billion-potential-why-kymera-therapeutics-kymr-might-be-the-biggest-sleeper-stock-in-biotech/"
X Link 2025-08-06T16:39Z [---] followers, [---] engagements
"$CRNX Analysts are piling into @Crinetics as it disrupts rare disease treatment. Discover the stock with 132% upside before it goes mainstream. https://biotechhealthx.com/biotech-news/wall-streets-best-kept-biotech-secret-crinetics-crnx-could-be-the-next-10x-stock/ https://biotechhealthx.com/biotech-news/wall-streets-best-kept-biotech-secret-crinetics-crnx-could-be-the-next-10x-stock/"
X Link 2025-08-06T16:40Z [---] followers, [---] engagements
"$LLY With its innovative pipeline and consistent financial success @EliLillyandCo is the pharmaceutical stock to watch. Find out why investors love it https://biotechhealthx.com/biotech-news/heres-why-eli-lilly-lly-is-the-pharma-stock-everyone-is-talking-about-right-now/ https://biotechhealthx.com/biotech-news/heres-why-eli-lilly-lly-is-the-pharma-stock-everyone-is-talking-about-right-now/"
X Link 2025-08-08T13:46Z [---] followers, [--] engagements
"$RCEL @AvitaMedical's RECELL System has already made an impact and with expanding applications investors can expect big returns. See more here https://biotechhealthx.com/biotech-news/avita-medical-rcel-is-delivering-big-returns-for-early-investors-heres-why-you-should-buy-this-now/ https://biotechhealthx.com/biotech-news/avita-medical-rcel-is-delivering-big-returns-for-early-investors-heres-why-you-should-buy-this-now/"
X Link 2025-08-08T13:47Z [---] followers, [---] engagements
"$KURA @kuraoncology's ZIFTOMENIB is poised to become a breakthrough drug in the treatment of acute myeloid leukemia (AML). Learn about it more here https://biotechhealthx.com/biotech-news/kura-oncology-kuras-targeted-therapies-could-dominate-the-market/ https://biotechhealthx.com/biotech-news/kura-oncology-kuras-targeted-therapies-could-dominate-the-market/"
X Link 2025-08-08T13:48Z [---] followers, [---] engagements
"$VSTM @VerastemOncolog 's targeted therapies are offering hope for patients with limited treatment options. Learn how it can change the game for cancer care. https://biotechhealthx.com/biotech-news/heres-why-verastem-vstm-is-the-next-big-thing-in-oncology/ https://biotechhealthx.com/biotech-news/heres-why-verastem-vstm-is-the-next-big-thing-in-oncology/"
X Link 2025-08-08T14:51Z [---] followers, [---] engagements
"$ASMB Discover how Assembly Biosciences is revolutionizing chronic viral disease treatments with cutting-edge therapeutics targeting HBV HDV etc. https://biotechhealthx.com/biotech-news/assembly-bio-asmb-the-future-of-chronic-viral-disease-treatment-is-here/ https://biotechhealthx.com/biotech-news/assembly-bio-asmb-the-future-of-chronic-viral-disease-treatment-is-here/"
X Link 2025-08-08T14:51Z [---] followers, [---] engagements
"$SLDB Solid Biosciences is developing the next-generation gene therapy for Duchenne muscular dystrophy with SGT-003 showing strong early results. https://biotechhealthx.com/biotech-news/the-future-of-gene-therapy-is-here-with-solid-biosciences-sldb-a-look-at-sgt-003/ https://biotechhealthx.com/biotech-news/the-future-of-gene-therapy-is-here-with-solid-biosciences-sldb-a-look-at-sgt-003/"
X Link 2025-08-08T14:53Z [---] followers, [---] engagements
"$TRIB From cutting-edge diagnostics to real-time health monitoring @TrinityBiotech's global expansion & tech pivot could send its growth soaring. https://biotechhealthx.com/biotech-news/trinity-biotech-trib-could-be-the-next-billion-dollar-healthcare-innovator/ https://biotechhealthx.com/biotech-news/trinity-biotech-trib-could-be-the-next-billion-dollar-healthcare-innovator/"
X Link 2025-08-14T16:05Z [---] followers, [--] engagements
"$RSLS Discover how the union of @ReShapeLifesci's obesity solutions and @VyomeTx's biotech pipeline could disrupt multi-billion-dollar markets worldwide. https://biotechhealthx.com/biotech-news/reshape-lifesciences-vyome-merger-could-create-a-healthcare-powerhouse/ https://biotechhealthx.com/biotech-news/reshape-lifesciences-vyome-merger-could-create-a-healthcare-powerhouse/"
X Link 2025-08-14T16:07Z [---] followers, [--] engagements
"$IMAB I-Mabs innovative drug pipeline & strategic alliances could make it one of the most explosive growth stories in healthcare. https://biotechhealthx.com/biotech-news/why-i-mab-imab-could-be-the-next-big-breakout-in-global-biotech/ https://biotechhealthx.com/biotech-news/why-i-mab-imab-could-be-the-next-big-breakout-in-global-biotech/"
X Link 2025-08-14T16:07Z [---] followers, [---] engagements
"$CVKD Tecarfarins unique design and regulatory fast-track status could make Cadrenal the most exciting growth story in biopharma right now. https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-inc-nasdaqcvkd/ https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-inc-nasdaqcvkd/"
X Link 2025-08-14T16:10Z [---] followers, [--] engagements
"$CVM @CelSciCorp is on the verge of making Multikine available in Saudi Arabia within [--] days. This move could skyrocket the companys growth. https://biotechhealthx.com/biotech-news/saudi-arabia-deal-could-catapult-cel-sci-cvm-into-global-biotech-spotlight/ https://biotechhealthx.com/biotech-news/saudi-arabia-deal-could-catapult-cel-sci-cvm-into-global-biotech-spotlight/"
X Link 2025-08-18T01:05Z [---] followers, [---] engagements
"$NERV Minerva Neurosciences engages the FDA for its pivotal trial potentially reshaping treatment for negative symptoms of schizophrenia. https://biotechhealthx.com/biotech-news/schizophrenia-breakthrough-alert-minerva-neurosciences-nervs-roluperidone-gains-fda-attention/ https://biotechhealthx.com/biotech-news/schizophrenia-breakthrough-alert-minerva-neurosciences-nervs-roluperidone-gains-fda-attention/"
X Link 2025-08-18T01:05Z [---] followers, [--] engagements
"$CYCN @Cyclerion is transforming its sGC stimulator portfolio into a revenue powerhouse while building a next-generation CNS pipeline. https://biotechhealthx.com/biotech-news/cyclerion-therapeutics-cycn-poised-for-massive-growth-with-1-75m-license-deal/ https://biotechhealthx.com/biotech-news/cyclerion-therapeutics-cycn-poised-for-massive-growth-with-1-75m-license-deal/"
X Link 2025-08-18T11:39Z [---] followers, [---] engagements
"$OTLK With a resubmitted BLA and prior EU approval Outlook Therapeutics could revolutionize wet AMD treatment. Learn about it more here https://biotechhealthx.com/biotech-news/will-lytenava-make-history-outlook-therapeutics-otlks-big-fda-moment-approaches/ https://biotechhealthx.com/biotech-news/will-lytenava-make-history-outlook-therapeutics-otlks-big-fda-moment-approaches/"
X Link 2025-08-18T11:40Z [---] followers, [---] engagements
"$BSX Boston Scientific is being hailed as a forever stock with unstoppable growth in AI cardiology and global markets. Learn more here https://biotechhealthx.com/biotech-news/analysts-call-boston-scientific-bsx-a-forever-company-for-investors/ https://biotechhealthx.com/biotech-news/analysts-call-boston-scientific-bsx-a-forever-company-for-investors/"
X Link 2025-08-20T18:18Z [---] followers, [--] engagements
"$JNJ Despite its strong brand and market dominance @JNJNews premium valuation may crumble under regulatory and legal weight. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-trading-near-highs-but-analysts-warn-of-a-reality-check/ https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-trading-near-highs-but-analysts-warn-of-a-reality-check/"
X Link 2025-08-20T18:19Z [---] followers, [--] engagements
"$PVLA With a strong pipeline and insider ownership @PalvellaTX is quickly becoming one of the most promising biotech stocks of [----]. https://biotechhealthx.com/biotech-news/investors-are-betting-big-on-palvella-therapeutics-pvla/ https://biotechhealthx.com/biotech-news/investors-are-betting-big-on-palvella-therapeutics-pvla/"
X Link 2025-08-24T07:49Z [---] followers, [---] engagements
"$KALA With KPI-012 data looming and only a year of cash left @KalaPharma future hangs by a thread. Could [----] be its last chance https://biotechhealthx.com/biotech-news/kala-pharma-kala-faces-make-or-break-2025-will-it-survive/ https://biotechhealthx.com/biotech-news/kala-pharma-kala-faces-make-or-break-2025-will-it-survive/"
X Link 2025-08-24T14:36Z [---] followers, [---] engagements
"$MRNA Once a pandemic hero @moderna_tx now faces collapsing demand political pressure and mounting losses. Can this biotech giant survive https://biotechhealthx.com/biotech-news/moderna-mrna-crashes-90-from-highs/ https://biotechhealthx.com/biotech-news/moderna-mrna-crashes-90-from-highs/"
X Link 2025-08-26T00:27Z [---] followers, [--] engagements
"$SLRX The Decoy Therapeutics merger adds more complexity but doesnt fix Salarius Pharmaceuticals' financial weaknesses dilution risks and regulatory problems. https://biotechhealthx.com/biotech-news/salarius-pharmaceuticals-slrx-merger-wont-save-it-from-trouble/ https://biotechhealthx.com/biotech-news/salarius-pharmaceuticals-slrx-merger-wont-save-it-from-trouble/"
X Link 2025-08-27T01:55Z [---] followers, [---] engagements
"$SER Analysts see Serina Therapeutics surging as its unique POZ technology delivers long-acting therapies for neurological diseases with huge unmet need. https://biotechhealthx.com/biotech-news/wall-street-predicts-130-upside-for-serina-therapeutics-ser/ https://biotechhealthx.com/biotech-news/wall-street-predicts-130-upside-for-serina-therapeutics-ser/"
X Link 2025-08-29T01:57Z [---] followers, [--] engagements
"$CRNX Wall Street is betting big on @Crinetics with strong buy ratings and price targets that more than double its current share price. Heres why. https://biotechhealthx.com/biotech-news/analysts-predict-over-100-upside-by-2026-for-crinetics-pharma-crnx/ https://biotechhealthx.com/biotech-news/analysts-predict-over-100-upside-by-2026-for-crinetics-pharma-crnx/"
X Link 2025-08-29T01:58Z [---] followers, [---] engagements
"$PHAT Voquezna is @phathompharma only approved drug carrying both massive upside & massive risk. Wall Street is divided on the companys future. https://biotechhealthx.com/biotech-news/phathom-pharma-phats-future-hangs-on-a-single-pill/ https://biotechhealthx.com/biotech-news/phathom-pharma-phats-future-hangs-on-a-single-pill/"
X Link 2025-08-29T01:59Z [---] followers, [--] engagements
"$EBS @EmergBsolutions secured $30M in BARDA funding but weak revenues and past scandals suggest investors should brace for more downside. https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-could-keep-sinking-despite-new-contracts/ https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-could-keep-sinking-despite-new-contracts/"
X Link 2025-09-03T17:44Z [---] followers, [---] engagements
"$AUPH After hitting new highs @AuriniaPharma's revenue growth profitability and biotech pipeline suggest even greater upside for investors ahead. https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-52-week-high/ https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-52-week-high/"
X Link 2025-09-05T04:23Z [---] followers, [---] engagements
"$IDYA With $210M upfront and $320M milestones Ideaya and Servier push for global approval of darovasertib in uveal melanoma. https://biotechhealthx.com/biotech-news/ideaya-idyas-530m-servier-deal-could-transform-cancer-care/ https://biotechhealthx.com/biotech-news/ideaya-idyas-530m-servier-deal-could-transform-cancer-care/"
X Link 2025-09-07T16:47Z [---] followers, [---] engagements
"$ACET @AdicetBio ended Q1 [----] with $150.4M in cash but faces rising losses of $28.2M. Can it last long enough for its Phase [--] CAR T data to deliver https://biotechhealthx.com/biotech-news/adicet-acet-falls-despite-150-4m-cash-runway-into-2026/ https://biotechhealthx.com/biotech-news/adicet-acet-falls-despite-150-4m-cash-runway-into-2026/"
X Link 2025-09-16T08:12Z [---] followers, [---] engagements
"$SLS @SellasLife raises $23.6M through warrant exercises boosting cash runway as GPS immunotherapy enters Phase [--] & SLS009 prepares for AML expansion. https://biotechhealthx.com/biotech-news/sellas-life-sls-secures-23-6m-to-fuel-late-stage-cancer-trials/ https://biotechhealthx.com/biotech-news/sellas-life-sls-secures-23-6m-to-fuel-late-stage-cancer-trials/"
X Link 2025-09-17T15:13Z [---] followers, [---] engagements
"$NVO @novonordisk plunged from $69 to $53.94 on July [--] [----]. Can the GLP-1 leader in Ozempic and Wegovy rebound in the $100B obesity market https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-21-83-in-one-day/ https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-crashes-21-83-in-one-day/"
X Link 2025-09-18T03:57Z [---] followers, [---] engagements
"$UNH EPS for @UnitedHealthGrp is projected at just $2.87 this quarter down from $6.80 last year raising serious doubts about near-term performance. https://biotechhealthx.com/biotech-news/unitedhealth-unhs-q3-earnings-forecast-crashes-nearly-60/ https://biotechhealthx.com/biotech-news/unitedhealth-unhs-q3-earnings-forecast-crashes-nearly-60/"
X Link 2025-09-19T05:25Z [---] followers, [---] engagements
"$OSCR Despite an EPS miss of -$0.89 @OscarHealth grew revenue 29% YoY fueling optimism for its digital-first insurance model and long-term gains. https://biotechhealthx.com/biotech-news/oscar-health-oscr-reports-2-86b-revenue-in-q2-2025/ https://biotechhealthx.com/biotech-news/oscar-health-oscr-reports-2-86b-revenue-in-q2-2025/"
X Link 2025-09-19T05:26Z [---] followers, [---] engagements
"$NTLA With an average target price of $34.14 @intelliatx could more than double as gene editing therapies near pivotal data in [----]. https://biotechhealthx.com/biotech-news/analysts-see-127-upside-for-intellia-ntla-after-14-99-surge/ https://biotechhealthx.com/biotech-news/analysts-see-127-upside-for-intellia-ntla-after-14-99-surge/"
X Link 2025-09-19T05:26Z [---] followers, [---] engagements
"$MTSR @MetseraInc surged after @pfizer offered $47.50 per share in cash42% above its $33 closeplus up to $22.50 more tied to performance. https://biotechhealthx.com/biotech-news/metsera-mtsr-shares-soar-on-pfizers-7-3b-buyout/ https://biotechhealthx.com/biotech-news/metsera-mtsr-shares-soar-on-pfizers-7-3b-buyout/"
X Link 2025-09-22T07:11Z [---] followers, [--] engagements
"$HROW By capping patient costs at $59 @Harrowhealth removes affordability barriers boosting refill rates and fueling long-term revenue growth. https://biotechhealthx.com/biotech-news/harrow-health-hrow-gains-momentum-with-59-cap-on-out-of-pocket-costs/ https://biotechhealthx.com/biotech-news/harrow-health-hrow-gains-momentum-with-59-cap-on-out-of-pocket-costs/"
X Link 2025-09-26T15:43Z [---] followers, [--] engagements
"$MLTX Patients on sonelokimab doubled response rates vs. placebo in hidradenitis suppurativa. Wall Street watches MoonLake Immunotherapeutics ahead of FDA talks. https://biotechhealthx.com/biotech-news/moonlake-mltxs-sonelokimab-crushes-phase-3-goals-with-35-response-rate-in-hs/ https://biotechhealthx.com/biotech-news/moonlake-mltxs-sonelokimab-crushes-phase-3-goals-with-35-response-rate-in-hs/"
X Link 2025-09-29T05:07Z [---] followers, [---] engagements
"$NVO @novonordiskfond posted $48.5 billion in revenue for [----] fueled by soaring demand for Ozempic and Wegovy. Can NVO maintain growth into [----] https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-surges-as-ozempic-and-wegovy-drive-48-5b-in-2025-sales/ https://biotechhealthx.com/biotech-news/novo-nordisk-nvo-surges-as-ozempic-and-wegovy-drive-48-5b-in-2025-sales/"
X Link 2025-09-29T05:07Z [---] followers, [---] engagements
"$JNJ @JNJNews stock is up 22% this year yet analysts say it remains fairly valued with room to climb. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-up-22-in-2025/ https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-is-up-22-in-2025/"
X Link 2025-09-29T05:08Z [---] followers, [--] engagements
"$PFE @pfizer announced a $70 billion investment in R&D and U.S. manufacturing a bold move to drive innovation after a 10% stock decline this year. https://biotechhealthx.com/biotech-news/pfizer-pfe-secures-70b-rd-push/ https://biotechhealthx.com/biotech-news/pfizer-pfe-secures-70b-rd-push/"
X Link 2025-10-01T05:21Z [---] followers, [--] engagements
"$XLV Health Care ETF (XLV) has beaten the S&P [---] in over half of the past [--] years. Heres why Wall Street calls it the ultimate healthcare growth and defense ETF. https://biotechhealthx.com/biotech-news/health-care-select-sector-spdr-fund-nysexlv/ https://biotechhealthx.com/biotech-news/health-care-select-sector-spdr-fund-nysexlv/"
X Link 2025-10-01T05:22Z [---] followers, [--] engagements
"$CRMD The $325$350M [----] revenue guidance shows CorMedixs transformation from a one-drug biotech into a diversified infectious disease leader. https://biotechhealthx.com/biotech-news/cormedix-crmd-revenue-to-hit-350m-after-melinta-buyout/ https://biotechhealthx.com/biotech-news/cormedix-crmd-revenue-to-hit-350m-after-melinta-buyout/"
X Link 2025-10-02T12:57Z [---] followers, [--] engagements
"$NVAX @Novavax amends its @sanofi collaboration unlocking up to $200M plus $210M per vaccine milestone payments and ongoing royalties. https://biotechhealthx.com/biotech-news/novavax-nvax-expands-200m-sanofi-deal-with-matrix-m-adjuvant/ https://biotechhealthx.com/biotech-news/novavax-nvax-expands-200m-sanofi-deal-with-matrix-m-adjuvant/"
X Link 2025-10-03T08:03Z [---] followers, [---] engagements
"$INSM FDA approves Brinsupri as the first therapy for NCFB. @Insmed rallies to $149.20 with Wall Street setting price targets as high as $240. https://biotechhealthx.com/biotech-news/insmed-insm-jumps-to-149-20-high-after-fda-approval-of-brinsupri/ https://biotechhealthx.com/biotech-news/insmed-insm-jumps-to-149-20-high-after-fda-approval-of-brinsupri/"
X Link 2025-10-03T08:04Z [---] followers, [---] engagements
"$UNH @UnitedHealthGrp delivers $111.62 billion in revenue yet EPS falls short spotlighting margin challenges in a costly healthcare climate. https://biotechhealthx.com/biotech-news/unitedhealth-unh-posts-111-62b-q2-revenue-but-earnings-disappoint/ https://biotechhealthx.com/biotech-news/unitedhealth-unh-posts-111-62b-q2-revenue-but-earnings-disappoint/"
X Link 2025-10-11T01:54Z [---] followers, [---] engagements
"$EBS Down from $1B in prior years @EmergentLabsHQ's trailing twelve-month revenue exposes how hard its recovery journey has become. https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-faces-investor-pressure-after-revenue-drops-to-0-81b-ttm/ https://biotechhealthx.com/biotech-news/emergent-biosolutions-ebs-faces-investor-pressure-after-revenue-drops-to-0-81b-ttm/"
X Link 2025-10-11T01:55Z [---] followers, [---] engagements
"$TNXP @TonixPharma shares fall despite FDA approval for Tonmya. Analysts say the sell-off could be a golden opportunity for long-term investors. https://biotechhealthx.com/biotech-news/tonix-pharmaceuticals-tnxp-plunges-20-after-fda-win/ https://biotechhealthx.com/biotech-news/tonix-pharmaceuticals-tnxp-plunges-20-after-fda-win/"
X Link 2025-10-14T10:37Z [---] followers, [---] engagements
"$AGIO With PYRUKYND poised for label expansion and Phase [--] trial results ahead Agios Pharmaceuticals may deliver serious upside. https://biotechhealthx.com/biotech-news/agios-agio-could-explode-in-2025-and-its-not-just-hype/ https://biotechhealthx.com/biotech-news/agios-agio-could-explode-in-2025-and-its-not-just-hype/"
X Link 2025-07-06T17:30Z [---] followers, [---] engagements
"$PHVS @pharvaris NV is targeting a massive untapped opportunity with its oral HAE therapy. Heres why early investors are buying in. https://biotechhealthx.com/biotech-news/pharvaris-phvs-the-300m-biotech-that-could-be-the-next-big-thing-in-pharma/ https://biotechhealthx.com/biotech-news/pharvaris-phvs-the-300m-biotech-that-could-be-the-next-big-thing-in-pharma/"
X Link 2025-07-19T03:39Z [---] followers, [--] engagements
"$NATR With strong Q1 results a conservative outlook and global tailwinds Nature's Shine could be one of the best small-cap opportunities this year. https://biotechhealthx.com/biotech-news/natures-sunshine-natr-is-crushing-expectations-is-a-2025-rally-imminent/ https://biotechhealthx.com/biotech-news/natures-sunshine-natr-is-crushing-expectations-is-a-2025-rally-imminent/"
X Link 2025-07-20T17:06Z [---] followers, [--] engagements
"$KTTA Backed by institutional money and a best-in-class drug candidate @PasitheaTx may be poised for liftoff. Explore the bullish case now. https://biotechhealthx.com/biotech-news/pasithea-therapeutics-ktta-just-raised-5-million-is-this-the-spark-it-needed/ https://biotechhealthx.com/biotech-news/pasithea-therapeutics-ktta-just-raised-5-million-is-this-the-spark-it-needed/"
X Link 2025-07-20T17:07Z [---] followers, [---] engagements
"$ISRG Intuitive Surgical just proved real-time remote surgery is more than hype. Its da Vinci [--] sets the new gold standard in digital surgery. https://biotechhealthx.com/biotech-news/telesurgery-is-here-and-intuitive-surgical-isrg-owns-it/ https://biotechhealthx.com/biotech-news/telesurgery-is-here-and-intuitive-surgical-isrg-owns-it/"
X Link 2025-07-22T16:32Z [---] followers, [---] engagements
"$ATHE With a Phase III design meeting on deck and $1.1B peak sales potential Alterity Therapeutics could be on the verge of a breakout run. https://biotechhealthx.com/biotech-news/alterity-therapeutics-athe-is-one-fda-meeting-away-from-a-major-breakout/ https://biotechhealthx.com/biotech-news/alterity-therapeutics-athe-is-one-fda-meeting-away-from-a-major-breakout/"
X Link 2025-07-23T14:05Z [---] followers, [---] engagements
"$NAGE With groundbreaking NAD+ science and its first profitable quarter @niagenbio might be the stock that delivers huge returns in [----]. https://biotechhealthx.com/biotech-news/from-10-to-23-why-niagen-bioscience-nage-could-be-the-next-big-biotech-success-story/ https://biotechhealthx.com/biotech-news/from-10-to-23-why-niagen-bioscience-nage-could-be-the-next-big-biotech-success-story/"
X Link 2025-07-29T00:59Z [---] followers, [---] engagements
"$DRMA Dermata is making waves with its late-stage acne treatment and strategic NASDAQ compliance moves. Learn more about DRMA stock here. https://biotechhealthx.com/biotech-news/drma-stock-alert-why-dermata-therapeutics-drma-could-be-the-hidden-biotech-gem-of-2025/ https://biotechhealthx.com/biotech-news/drma-stock-alert-why-dermata-therapeutics-drma-could-be-the-hidden-biotech-gem-of-2025/"
X Link 2025-08-04T02:51Z [---] followers, [---] engagements
"$XCUR With new AML and multiple myeloma trials on the horizon @exicure's GPC-100 may change the game for blood cancer therapies. Learn more here https://biotechhealthx.com/biotech-news/exicure-xcurs-gpc-100-could-revolutionize-cancer-treatment-analysts-see-massive-upside-for-this-stock/ https://biotechhealthx.com/biotech-news/exicure-xcurs-gpc-100-could-revolutionize-cancer-treatment-analysts-see-massive-upside-for-this-stock/"
X Link 2025-08-04T02:52Z [---] followers, [---] engagements
"$MIRM @mirumpharma is on fire with soaring revenues and new clinical wins. Analysts say the stock is still cheapheres why it could double soon. https://biotechhealthx.com/biotech-news/from-0-to-300m-in-sales-mirum-pharmaceuticals-mirms-wild-ride-is-just-beginning/ https://biotechhealthx.com/biotech-news/from-0-to-300m-in-sales-mirum-pharmaceuticals-mirms-wild-ride-is-just-beginning/"
X Link 2025-08-06T16:39Z [---] followers, [--] engagements
"$SLGL Sol-Gel Technologies is on the brink of transforming skincare. This biotech company could redefine the future of dermatology treatments. https://biotechhealthx.com/biotech-news/can-sol-gel-technologies-slgl-become-the-next-big-name-in-dermatology/ https://biotechhealthx.com/biotech-news/can-sol-gel-technologies-slgl-become-the-next-big-name-in-dermatology/"
X Link 2025-08-08T14:52Z [---] followers, [---] engagements
"$IBRX @ImmunityBio just hit a major milestone with its cancer-fighting drug ANKTIVA. Heres why analysts believe this could send the stock soaring https://biotechhealthx.com/biotech-news/heres-why-wall-street-is-suddenly-obsessed-with-immunitybio-ibrx/ https://biotechhealthx.com/biotech-news/heres-why-wall-street-is-suddenly-obsessed-with-immunitybio-ibrx/"
X Link 2025-08-12T17:27Z [---] followers, [----] engagements
"$JAZZ The @Saniona_AB partnership gives @JazzPharma rights to SAN2355 a preclinical epilepsy drug. Is this a golden opportunity or a billion-dollar mistake https://biotechhealthx.com/biotech-news/jazz-pharmaceuticals-jazzs-latest-deal-could-make-or-break-its-entire-future/ https://biotechhealthx.com/biotech-news/jazz-pharmaceuticals-jazzs-latest-deal-could-make-or-break-its-entire-future/"
X Link 2025-08-20T18:16Z [---] followers, [---] engagements
"$ZBH @zimmerbiomet stock jumped to $107.71 but repeated guidance cuts and operational risks suggest this rally may not last long. https://biotechhealthx.com/biotech-news/zimmer-biomet-zbhs-3-gain-could-be-a-trap-for-investors/ https://biotechhealthx.com/biotech-news/zimmer-biomet-zbhs-3-gain-could-be-a-trap-for-investors/"
X Link 2025-08-24T07:48Z [---] followers, [--] engagements
"$LFVN @lifevantage expanded fast with its wellness products but investors are asking whether its MLM structure is sustainable. https://biotechhealthx.com/biotech-news/lifevantage-lfvn-faces-big-questions-despite-its-global-growth/ https://biotechhealthx.com/biotech-news/lifevantage-lfvn-faces-big-questions-despite-its-global-growth/"
X Link 2025-08-24T07:51Z [---] followers, [---] engagements
"$CORT Despite analyst optimism @Corcept shares plunged. Learn what triggered the drop and why it could signal deeper problems for investors. https://biotechhealthx.com/biotech-news/corcept-therapeutics-cort-crashed-monday-is-this-the-start-of-a-bigger-selloff/ https://biotechhealthx.com/biotech-news/corcept-therapeutics-cort-crashed-monday-is-this-the-start-of-a-bigger-selloff/"
X Link 2025-08-24T14:33Z [---] followers, [--] engagements
"$BBIO @BridgeBioPharma's pipeline looks strong but its rising expenses and insider sales raise red flags. Is BBIO headed for a crash https://biotechhealthx.com/biotech-news/bbio-stock-alert-can-bridgebio-pharma-survive-its-cash-burn/ https://biotechhealthx.com/biotech-news/bbio-stock-alert-can-bridgebio-pharma-survive-its-cash-burn/"
X Link 2025-08-24T14:45Z [---] followers, [---] engagements
"$EVOK With limited cash rising debt and no diversification Evoke Pharma may be at breaking point. Investors should brace for downside risk. https://biotechhealthx.com/biotech-news/evoke-pharma-evok-faces-harsh-reality-can-it-avoid-collapse/ https://biotechhealthx.com/biotech-news/evoke-pharma-evok-faces-harsh-reality-can-it-avoid-collapse/"
X Link 2025-08-24T14:46Z [---] followers, [--] engagements
"$SER Serina Therapeutics surged after FDA feedback on its Parkinsons candidate SER-252. Can this small-cap biotech turn into a billion-dollar winner https://biotechhealthx.com/biotech-news/serina-sers-parkinsons-drug-gets-fda-support-stock-investors-go-wild/ https://biotechhealthx.com/biotech-news/serina-sers-parkinsons-drug-gets-fda-support-stock-investors-go-wild/"
X Link 2025-08-26T00:26Z [---] followers, [--] engagements
"$HCA @HCAhealthcare has soared from $123 to over $400 per share. With rising earnings estimates can HCA keep climbing higher https://biotechhealthx.com/biotech-news/hca-healthcare-hca-surges-over-228-since-2019/ https://biotechhealthx.com/biotech-news/hca-healthcare-hca-surges-over-228-since-2019/"
X Link 2025-08-26T14:34Z [---] followers, [---] engagements
"$TTNP Titan Pharmaceuticals jumps on merger approval with Black Titan but poor financials weak cash runway and heavy dilution risks could crush long-term value. https://biotechhealthx.com/biotech-news/titan-pharmaceuticals-ttnp-merger-hype-vs-reality/ https://biotechhealthx.com/biotech-news/titan-pharmaceuticals-ttnp-merger-hype-vs-reality/"
X Link 2025-08-27T01:54Z [---] followers, [---] engagements
"$RADX @TeamRadiopharm uplisted to @Nasdaq with bold cancer treatment ambitions but early pipeline risks and cash burn make RADX a speculative play. https://biotechhealthx.com/biotech-news/radiopharm-radx-stock-high-risk-high-hype/ https://biotechhealthx.com/biotech-news/radiopharm-radx-stock-high-risk-high-hype/"
X Link 2025-08-27T01:57Z [---] followers, [---] engagements
"$GBIO With funding secured through [----] @generationbio has the runway to advance clinical trials without immediate dilution strengthening its bullish case. https://biotechhealthx.com/biotech-news/generation-bio-gbio-has-185m-in-cash-heres-why-that-matters/ https://biotechhealthx.com/biotech-news/generation-bio-gbio-has-185m-in-cash-heres-why-that-matters/"
X Link 2025-08-27T01:57Z [---] followers, [---] engagements
"$MOH Medicaid redeterminations shrinking enrollments and rising costs could derail Molina Healthcares dominance in government healthcare programs. https://biotechhealthx.com/biotech-news/molina-healthcare-mohs-medicaid-empire-faces-its-toughest-test-yet/ https://biotechhealthx.com/biotech-news/molina-healthcare-mohs-medicaid-empire-faces-its-toughest-test-yet/"
X Link 2025-08-29T02:01Z [---] followers, [---] engagements
"$TGTX With Briumvi sales projected to cross $1B by [----] @TGTherapeutics may be Wall Streets next biotech superstar. Heres the full story. https://biotechhealthx.com/biotech-news/tg-therapeutics-tgtx-can-be-the-next-1b-biotech-giant/ https://biotechhealthx.com/biotech-news/tg-therapeutics-tgtx-can-be-the-next-1b-biotech-giant/"
X Link 2025-09-03T17:42Z [---] followers, [----] engagements
"$HQY @HealthEquity just reported massive profit growth & record margins. This healthcare savings stock may be primed for even bigger gains. https://biotechhealthx.com/biotech-news/healthequity-hqy-crushes-earnings-with-67-profit-surge/ https://biotechhealthx.com/biotech-news/healthequity-hqy-crushes-earnings-with-67-profit-surge/"
X Link 2025-09-03T17:44Z [---] followers, [--] engagements
"$AVTX Avalo Therapeutics stock has jumped 45% in six months. With $113M cash Buy ratings and a $30 average target analysts project nearly 195% more upside. https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-surges-45-in-6-months/ https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-surges-45-in-6-months/"
X Link 2025-09-05T14:10Z [---] followers, [---] engagements
"$AXSM @axsome reported $150M Q2 revenue with EPS of $0.92 vs $1 expected. Strong Auvelity sales drove 72% YoY growth but net loss hit $48. https://biotechhealthx.com/biotech-news/axsome-axsm-posts-150m-q2-revenue-beats-eps-expectations/ https://biotechhealthx.com/biotech-news/axsome-axsm-posts-150m-q2-revenue-beats-eps-expectations/"
X Link 2025-09-05T14:11Z [---] followers, [---] engagements
"$OKYO @OkyoPharma's urcosimod delivered 75%+ pain reduction in neuropathic corneal pain patients and analyst upgrades with targets up to $8. https://biotechhealthx.com/biotech-news/okyo-pharma-okyo-surges-on-75-pain-reduction-in-phase-2-trial/ https://biotechhealthx.com/biotech-news/okyo-pharma-okyo-surges-on-75-pain-reduction-in-phase-2-trial/"
X Link 2025-09-07T17:33Z [---] followers, [---] engagements
"$SPRO Spero Therapeutics shares skyrocketed over 200% after tebipenem HBr hit efficacy goals in a 1690-patient Phase [--] trial. https://biotechhealthx.com/biotech-news/spero-therapeutics-spro-surges-after-200-stock-jump-on-phase-3-success/ https://biotechhealthx.com/biotech-news/spero-therapeutics-spro-surges-after-200-stock-jump-on-phase-3-success/"
X Link 2025-09-07T17:35Z [---] followers, [---] engagements
"$ADVM Analysts project @adverumbio Biotechnologies Inc. shares could climb from $3.52 to $19.75 with some targets as high as $33. https://biotechhealthx.com/biotech-news/adverum-advm-could-soar-460-with-19-75-target/ https://biotechhealthx.com/biotech-news/adverum-advm-could-soar-460-with-19-75-target/"
X Link 2025-09-07T17:36Z [---] followers, [---] engagements
"$CRVS @CorvusPharma reported a net loss of $8M in Q2 [----] nearly double last years $4.3M. Can soquelitinibs early trial data offset rising R&D costs https://biotechhealthx.com/biotech-news/corvus-pharmaceuticals-inc-nasdaqcrvs/ https://biotechhealthx.com/biotech-news/corvus-pharmaceuticals-inc-nasdaqcrvs/"
X Link 2025-09-13T15:34Z [---] followers, [---] engagements
"$NAGE Despite soaring 503% since [----] @niagenbio intrinsic value is only $4.04 per share. Is NAGE stock trading 133% above fair value https://biotechhealthx.com/biotech-news/niagen-bioscience-nage-up-503-in-3-years/ https://biotechhealthx.com/biotech-news/niagen-bioscience-nage-up-503-in-3-years/"
X Link 2025-09-13T15:35Z [---] followers, [---] engagements
"$ABVC @ABVCBioPharma reported 103% growth to $16.2M in Q2 [----] with shareholder equity up 18.7%. Investors eye its oncology pipeline for upside. https://biotechhealthx.com/biotech-news/abvc-biopharma-abvc-doubles-assets-to-16-2m-in-q2-2025/ https://biotechhealthx.com/biotech-news/abvc-biopharma-abvc-doubles-assets-to-16-2m-in-q2-2025/"
X Link 2025-09-15T05:57Z [---] followers, [--] engagements
"$MGTX @MeiraGTx posted a Q2 loss of ($0.48) EPS beat estimates by $0.04 with $3.69M revenue as late-stage programs fuel analyst optimism. https://biotechhealthx.com/biotech-news/meiragtx-mgtx-reports-3-69m-revenue/ https://biotechhealthx.com/biotech-news/meiragtx-mgtx-reports-3-69m-revenue/"
X Link 2025-09-16T08:10Z [---] followers, [---] engagements
"$PHGE In Phase [--] trials @BiomX_Inc's BX211 showed a 40% wound size reduction in diabetic foot osteomyelitis. Can this make PHGE the next biotech champ https://biotechhealthx.com/biotech-news/biomx-phge-surges-as-bx211-cuts-diabetic-wounds-by-40/ https://biotechhealthx.com/biotech-news/biomx-phge-surges-as-bx211-cuts-diabetic-wounds-by-40/"
X Link 2025-09-16T08:11Z [---] followers, [---] engagements
"$ENLV @EnlivexT narrowed its Q2 net loss to $1.87M from $3.1M last year reducing burn as Allocetra delivers strong clinical wins. https://biotechhealthx.com/biotech-news/enlivex-enlv-reports-1-87m-q2-loss-cuts-cash-burn-nearly-40/ https://biotechhealthx.com/biotech-news/enlivex-enlv-reports-1-87m-q2-loss-cuts-cash-burn-nearly-40/"
X Link 2025-09-16T08:12Z [---] followers, [--] engagements
"$ZYME @ZymeworksInc delivered a 153.2% YoY revenue increase and surprised Wall Street with $0.03 EPS. Analysts now eye $21.43 per share. https://biotechhealthx.com/biotech-news/zymeworks-zyme-reports-153-revenue-growth-beats-eps-expectations/ https://biotechhealthx.com/biotech-news/zymeworks-zyme-reports-153-revenue-growth-beats-eps-expectations/"
X Link 2025-09-22T07:12Z [---] followers, [--] engagements
"$FLGC @floragrowthcorp stock surged 69% after-hours as it rebrands to ZeroStack backing a $401M deal in AI and blockchain. https://biotechhealthx.com/biotech-news/flora-growth-flgc-soars-69-after-401m-ai-pivot/ https://biotechhealthx.com/biotech-news/flora-growth-flgc-soars-69-after-401m-ai-pivot/"
X Link 2025-09-22T07:13Z [---] followers, [--] engagements
"$FGEN @FibroGenInc (NASDAQ:FGEN) offloads FibroGen China for $160M extending cash runway into [----] while focusing on oncology trials. https://biotechhealthx.com/biotech-news/fibrogen-fgen-sells-china-arm-to-astrazeneca-in-160m-deal/ https://biotechhealthx.com/biotech-news/fibrogen-fgen-sells-china-arm-to-astrazeneca-in-160m-deal/"
X Link 2025-09-22T07:14Z [---] followers, [--] engagements
"$SLNO Soleno plunged 26% in a month after a short-seller attack but analysts still target $110$120. Is this oversold stock ready to rebound https://biotechhealthx.com/biotech-news/soleno-slno-oversold-after-26-drop/ https://biotechhealthx.com/biotech-news/soleno-slno-oversold-after-26-drop/"
X Link 2025-09-24T16:30Z [---] followers, [--] engagements
"$BCTX Fresh capital fuels @BriaCell's pipeline including Bria-IMT and Bria-OTS+ as it accelerates clinical trials in breast and prostate cancer. https://biotechhealthx.com/biotech-news/briacell-bctx-raises-13-8m-to-advance-cancer-immunotherapy-pipeline/ https://biotechhealthx.com/biotech-news/briacell-bctx-raises-13-8m-to-advance-cancer-immunotherapy-pipeline/"
X Link 2025-09-25T17:03Z [---] followers, [---] engagements
"$QLGN @Qualigen locks in a $41M PIPE from Faraday Future at $2.246/share. Will its oncology pipeline & crypto pivot drive the next biotech breakout https://biotechhealthx.com/biotech-news/qualigen-therapeutics-qlgn-secures-41m-faraday-future-deal/ https://biotechhealthx.com/biotech-news/qualigen-therapeutics-qlgn-secures-41m-faraday-future-deal/"
X Link 2025-09-25T17:04Z [---] followers, [--] engagements
"$SMMT Summit Therapeutics gained 14% this year as ivonescimab showed global trial success. Can it deliver the next big oncology breakthrough https://biotechhealthx.com/biotech-news/summit-therapeutics-smmt-up-14-ytd/ https://biotechhealthx.com/biotech-news/summit-therapeutics-smmt-up-14-ytd/"
X Link 2025-09-28T06:17Z [---] followers, [---] engagements
"$HUM @Humana hit with $32 million legal fee order after $90M settlement whats next for the $60B healthcare giant https://biotechhealthx.com/biotech-news/humana-hum-ordered-to-pay-32-million-in-whistleblower-case/ https://biotechhealthx.com/biotech-news/humana-hum-ordered-to-pay-32-million-in-whistleblower-case/"
X Link 2025-09-29T05:08Z [---] followers, [--] engagements
"$AUPH @AuriniaPharma rockets to a 52-week high at $13.45 capping an 80.56% one-year gain. Strong Q2 earnings and 80% margins fuel investor optimism. https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-13-45-52-week-high-after-80-surge/ https://biotechhealthx.com/biotech-news/aurinia-pharmaceuticals-auph-hits-13-45-52-week-high-after-80-surge/"
X Link 2025-09-30T04:55Z [---] followers, [---] engagements
"$FDMT CLO Scott Bizily sells $19256 in @4DMolecular shares but stock surged 27% this week. As Phase [--] trials begin is Goldmans $38 target next https://biotechhealthx.com/biotech-news/4d-molecular-therapeutics-insider-sells-19256-as-fdmt-surges-27-in-a-week/ https://biotechhealthx.com/biotech-news/4d-molecular-therapeutics-insider-sells-19256-as-fdmt-surges-27-in-a-week/"
X Link 2025-09-30T04:56Z [---] followers, [---] engagements
"$CVKD Cadrenal surged after acquiring frunexian a Phase 2-ready Factor XIa inhibitor. Analysts keep $30/share valuation despite early-stage risks. https://biotechhealthx.com/biotech-news/cadrenal-cvkd-targeted-at-30-after-acquiring-phase-2-ready-frunexian/ https://biotechhealthx.com/biotech-news/cadrenal-cvkd-targeted-at-30-after-acquiring-phase-2-ready-frunexian/"
X Link 2025-10-01T05:22Z [---] followers, [--] engagements
"$CORT @Corcept has delivered a jaw-dropping 1534% gain in the last decade. With FDA review of relacorilant underway can this stock keep climbing https://biotechhealthx.com/biotech-news/corcept-cort-skyrockets-1534-in-10-years/ https://biotechhealthx.com/biotech-news/corcept-cort-skyrockets-1534-in-10-years/"
X Link 2025-10-01T05:23Z [---] followers, [---] engagements
"$HALO With $1.179B in trailing revenue and royalties surging 65% YoY @halozymeinc is turning its ENHANZE platform into a biotech money engine. https://biotechhealthx.com/biotech-news/halozyme-halo-reports-1-179b-revenue-and-65-royalty-growth/ https://biotechhealthx.com/biotech-news/halozyme-halo-reports-1-179b-revenue-and-65-royalty-growth/"
X Link 2025-10-02T12:56Z [---] followers, [---] engagements
"$KZIA Despite working on glioblastoma & DIPG with median survival under [--] months Kazia trades below $1. Is Wall Street overlooking this stock https://biotechhealthx.com/biotech-news/kazia-kzia-trades-under-1-while-tackling-cancers-with-1-year-survival-rates/ https://biotechhealthx.com/biotech-news/kazia-kzia-trades-under-1-while-tackling-cancers-with-1-year-survival-rates/"
X Link 2025-10-02T12:59Z [---] followers, [---] engagements
"$DRMA Dermata secures Australian patent for its Spongilla-based acne treatment targeting [---] million acne patients. OTC launch set for mid-2026. https://biotechhealthx.com/biotech-news/dermata-drma-wins-australian-patent-for-acne-therapy/ https://biotechhealthx.com/biotech-news/dermata-drma-wins-australian-patent-for-acne-therapy/"
X Link 2025-10-02T12:59Z [---] followers, [---] engagements
"$RXRX Needham analyst Gil Blum reiterated a Buy on @RecursionPharma with a $8 target highlighting AI partnerships and a growing clinical pipeline. https://biotechhealthx.com/biotech-news/recursion-pharmaceuticals-stock-could-double-with-8-price-target/ https://biotechhealthx.com/biotech-news/recursion-pharmaceuticals-stock-could-double-with-8-price-target/"
X Link 2025-10-03T08:02Z [---] followers, [---] engagements
"$NCNA @NuCana_news just removed all Series A Warrants improving financial clarity and positioning itself for major [----] milestone results. https://biotechhealthx.com/biotech-news/nucana-ncna-completes-3-6m-warrant-buyout/ https://biotechhealthx.com/biotech-news/nucana-ncna-completes-3-6m-warrant-buyout/"
X Link 2025-10-07T17:22Z [---] followers, [---] engagements
"$CADL Analysts see Candel Therapeutics hitting $20.06272% higher than $5.39on viral immunotherapy breakthroughs led by CAN-2409 and CAN-3110. https://biotechhealthx.com/biotech-news/candel-therapeutics-cadl-poised-for-272-upside/ https://biotechhealthx.com/biotech-news/candel-therapeutics-cadl-poised-for-272-upside/"
X Link 2025-10-09T04:28Z [---] followers, [---] engagements
"$CRSP Analysts project massive upside as CRISPR Therapeutics Casgevy becomes the first gene-editing cure for sickle-cell and thalassemia. https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/ https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/"
X Link 2025-10-09T04:29Z [---] followers, [---] engagements
"$CRSP Analysts project massive upside as CRISPR Therapeutics Casgevy becomes the first gene-editing cure for sickle-cell and thalassemia. https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/ https://biotechhealthx.com/biotech-news/wall-street-sees-272-upside-for-crispr-therapeutics-crsp-after-historic-fda-win/"
X Link 2025-10-09T04:29Z [---] followers, [---] engagements
"$REGN The Phase [--] C-POST trial proved Libtayo cut cancer recurrence risk by 68% yet @Regeneron tumbled 3%. What spooked investors https://biotechhealthx.com/biotech-news/regeneron-regns-68-efficacy-breakthrough-fails-to-impress-wall-street/ https://biotechhealthx.com/biotech-news/regeneron-regns-68-efficacy-breakthrough-fails-to-impress-wall-street/"
X Link 2025-10-09T04:29Z [---] followers, [--] engagements
"$TPST With $14.3M in cash Tempest Therapeutics strengthens its position before launching its most ambitious liver cancer study yet. https://biotechhealthx.com/biotech-news/tempest-therapeutics-tpst-boosts-cash-with-4-6m-raise-ahead-of-cancer-trial/ https://biotechhealthx.com/biotech-news/tempest-therapeutics-tpst-boosts-cash-with-4-6m-raise-ahead-of-cancer-trial/"
X Link 2025-10-09T04:30Z [---] followers, [---] engagements
"$ELV Trading at just [-----] forward earnings vs. the industrys [----] @ElevanceHealth's strategy could offer a major rebound opportunity. https://biotechhealthx.com/biotech-news/elevance-health-elv-down-14-6-ytd/ https://biotechhealthx.com/biotech-news/elevance-health-elv-down-14-6-ytd/"
X Link 2025-10-09T04:32Z [---] followers, [--] engagements
"$ARGX @argenxglobal soared to $803.95 fueled by 88% year-over-year revenue growth and record Vyvgart sales. Can the $45B biotech keep its momentum https://biotechhealthx.com/biotech-news/argenx-se-argx-hits-803-95-all-time-high-after-88-revenue-surge/ https://biotechhealthx.com/biotech-news/argenx-se-argx-hits-803-95-all-time-high-after-88-revenue-surge/"
X Link 2025-10-09T10:46Z [---] followers, [---] engagements
"$ACON Out of [----] digital health innovators @aclarioninc Nociscan shines as a finalist in the Clinical Diagnostic Device category at HLTH [----]. https://biotechhealthx.com/biotech-news/aclarion-acon-emerges-as-rising-star-in-ai-diagnostics-at-hlth-2025-awards/ https://biotechhealthx.com/biotech-news/aclarion-acon-emerges-as-rising-star-in-ai-diagnostics-at-hlth-2025-awards/"
X Link 2025-10-11T01:54Z [---] followers, [---] engagements
"$AXGN Revenue jumped 17.4% year-over-year as Axogen nears its FDA BLA decision. Analysts project up to 60% upside before the December [--] ruling. https://biotechhealthx.com/biotech-news/axogen-axgn-surges-toward-26-target-as-nerve-repair-demand-soars-17/ https://biotechhealthx.com/biotech-news/axogen-axgn-surges-toward-26-target-as-nerve-repair-demand-soars-17/"
X Link 2025-10-12T17:05Z [---] followers, [--] engagements
"$LH With EPS set to jump 82% this year investors see upside for @Labcorp's $19.5B diagnostics empire. https://biotechhealthx.com/biotech-news/labcorp-lh-trades-near-210-as-investors-bet-on-82-earnings-boom/ https://biotechhealthx.com/biotech-news/labcorp-lh-trades-near-210-as-investors-bet-on-82-earnings-boom/"
X Link 2025-10-12T17:08Z [---] followers, [--] engagements
"$ALDX @AldeyraALDX's shares dip under $5.40 ahead of the December [--] FDA ruling on reproxalap will approval save the company https://biotechhealthx.com/biotech-news/aldeyra-therapeutics-aldx-falls-below-5-40-as-fda-decision-looms/ https://biotechhealthx.com/biotech-news/aldeyra-therapeutics-aldx-falls-below-5-40-as-fda-decision-looms/"
X Link 2025-10-12T17:09Z [---] followers, [---] engagements
"$GALT With belapectin showing a 49% reduction in varices @GalectinGALT targets a massive untapped market with no approved therapies. https://biotechhealthx.com/biotech-news/inside-galectin-galts-18-billion-shot-at-reversing-liver-cirrhosis/ https://biotechhealthx.com/biotech-news/inside-galectin-galts-18-billion-shot-at-reversing-liver-cirrhosis/"
X Link 2025-10-13T18:30Z [---] followers, [---] engagements
"$TENX With $105.5M in cash @TenaxThera is advancing two Phase [--] trials that could deliver the first therapy for PH-HFpEF by [----]. https://biotechhealthx.com/biotech-news/tenax-therapeutics-tenx-fully-funded-through-2027-with-105-5m-cash/ https://biotechhealthx.com/biotech-news/tenax-therapeutics-tenx-fully-funded-through-2027-with-105-5m-cash/"
X Link 2025-10-13T18:33Z [---] followers, [---] engagements
"$MOH Molina Healthcares shares plunged 39.31% in [--] months after cutting EPS guidance amid soaring medical costs. Is a turnaround possible https://biotechhealthx.com/biotech-news/molina-healthcare-moh-crashes-39-in-a-year/ https://biotechhealthx.com/biotech-news/molina-healthcare-moh-crashes-39-in-a-year/"
X Link 2025-10-14T10:35Z [---] followers, [---] engagements
"$AZN @AstraZeneca eyes $80B in annual revenue by [----] driven by [--] new drug launches and booming oncology sales. https://biotechhealthx.com/biotech-news/astrazeneca-azn-targets-80-billion-revenue-by-2030/ https://biotechhealthx.com/biotech-news/astrazeneca-azn-targets-80-billion-revenue-by-2030/"
X Link 2025-10-14T10:37Z [---] followers, [--] engagements
"$TDOC After its $18.5B Livongo deal @TeladocHealth's new AI system positions it as the leader in next-gen hospital safety and virtual care. https://biotechhealthx.com/biotech-news/teladoc-tdocs-ai-upgrade-could-be-its-biggest-breakthrough-since-livongo/ https://biotechhealthx.com/biotech-news/teladoc-tdocs-ai-upgrade-could-be-its-biggest-breakthrough-since-livongo/"
X Link 2025-10-15T12:39Z [---] followers, [---] engagements
"$RADX @TeamRadiopharm shares paused before key capital raise to fund Phase [--] cancer trials market cap A$85.1M. https://biotechhealthx.com/biotech-news/radiopharm-theranostics-radx-halts-trading-ahead-of-major-capital-raise/ https://biotechhealthx.com/biotech-news/radiopharm-theranostics-radx-halts-trading-ahead-of-major-capital-raise/"
X Link 2025-10-15T12:40Z [---] followers, [---] engagements
"$TEVA The FDA just expanded UZEDYs use to bipolar I disorder giving @TevaPharmaDC access to a $4.X.5B U.S. psychiatric market. https://biotechhealthx.com/biotech-news/teva-pharma-teva-wins-fda-approval-for-uzedys-bipolar-i-expansion/ https://biotechhealthx.com/biotech-news/teva-pharma-teva-wins-fda-approval-for-uzedys-bipolar-i-expansion/"
X Link 2025-10-15T12:41Z [---] followers, [---] engagements
"$RMD With [--] billion people affected by sleep apnea @Resmed is positioned for explosive growth. See why ResMed is a smart long-term investment. https://biotechhealthx.com/biotech-news/resmed-rmd-dominates-39-7-billion-sleep-health-market/ https://biotechhealthx.com/biotech-news/resmed-rmd-dominates-39-7-billion-sleep-health-market/"
X Link 2025-10-19T06:18Z [---] followers, [---] engagements
"$DCTH High-margin model and strong cash position set stage for Delcath Systems' rapid commercial growth. Check this out https://biotechhealthx.com/biotech-news/delcath-dcth-revenue-surges-with-87-gross-margin-and-zero-debt-balance-sheet/ https://biotechhealthx.com/biotech-news/delcath-dcth-revenue-surges-with-87-gross-margin-and-zero-debt-balance-sheet/"
X Link 2025-10-19T06:19Z [---] followers, [---] engagements
"$VNDA Analysts see Vanda Pharmaceuticals' shares surging to $20 from $5.10 as FDA collaboration signals regulatory turnaround. https://biotechhealthx.com/biotech-news/vanda-pharmaceuticals-vnda-targets-300-upside-with-breakthrough-fda-framework-deal/ https://biotechhealthx.com/biotech-news/vanda-pharmaceuticals-vnda-targets-300-upside-with-breakthrough-fda-framework-deal/"
X Link 2025-10-19T06:20Z [---] followers, [---] engagements
"$DRUG Trading near 86.1% of its 52-week high @brightmindsbio is poised for a major breakout backed by strong fundamentals. https://biotechhealthx.com/biotech-news/bright-minds-biosciences-drug-surges-158-8-in-12-weeks/ https://biotechhealthx.com/biotech-news/bright-minds-biosciences-drug-surges-158-8-in-12-weeks/"
X Link 2025-10-19T06:21Z [---] followers, [--] engagements
"$RKDA Arcadia Biosciences financial losses are accelerating despite its stock rally. Heres what Wall Street isnt telling you. https://biotechhealthx.com/biotech-news/arcadia-biosciences-rkda-surges-53-but-ebitda-is-still-5-9-million/ https://biotechhealthx.com/biotech-news/arcadia-biosciences-rkda-surges-53-but-ebitda-is-still-5-9-million/"
X Link 2025-10-19T06:22Z [---] followers, [--] engagements
"$ADXN Strategic partnerships and breakthrough neuroscience pipeline fuel @AddexPharma's massive upside potential. https://biotechhealthx.com/biotech-news/addex-therapeutics-adxn-targets-330-million-milestone-payouts/ https://biotechhealthx.com/biotech-news/addex-therapeutics-adxn-targets-330-million-milestone-payouts/"
X Link 2025-10-19T06:22Z [---] followers, [--] engagements
"$SLS Late-stage trial momentum of SELLAS Life Sciences Group fuels buyout speculation from Wall Street. Check this out https://biotechhealthx.com/biotech-news/sellas-sls-surged-40-after-hours-on-new-aml-data/ https://biotechhealthx.com/biotech-news/sellas-sls-surged-40-after-hours-on-new-aml-data/"
X Link 2025-10-19T06:37Z [---] followers, [---] engagements
"$TENX Investors are flocking to Tenax Therapeutics for its rare financial strength and high-growth pipeline. Check this out https://biotechhealthx.com/biotech-news/tenax-tenx-could-be-the-best-funded-microcap-in-biotech/ https://biotechhealthx.com/biotech-news/tenax-tenx-could-be-the-best-funded-microcap-in-biotech/"
X Link 2025-10-21T03:24Z [---] followers, [---] engagements
"$ADXN @AddexPharma regains global drug rights and targets multi-billion-dollar markets in neurology. Early investors are watching closely. https://biotechhealthx.com/biotech-info/addex-therapeutics-adxn-is-on-the-brink-of-a-breakout/ https://biotechhealthx.com/biotech-info/addex-therapeutics-adxn-is-on-the-brink-of-a-breakout/"
X Link 2025-10-26T07:15Z [---] followers, [--] engagements
"$NEUP Institutional interest is rising as Neuphoria Therapeutics nears a critical data readout. Click this article to know more https://biotechhealthx.com/biotech-info/hedge-funds-are-quietly-loading-up-on-neuphoria-neup/ https://biotechhealthx.com/biotech-info/hedge-funds-are-quietly-loading-up-on-neuphoria-neup/"
X Link 2025-10-26T07:17Z [---] followers, [--] engagements
"$ARMP Armata Pharmaceuticals surged 103% after landmark clinical results shocked Wall Street. Read this article to know more information. https://biotechhealthx.com/biotech-news/armata-pharma-armp-skyrockets-103-in-one-day/ https://biotechhealthx.com/biotech-news/armata-pharma-armp-skyrockets-103-in-one-day/"
X Link 2025-10-26T07:57Z [---] followers, [--] engagements
"$ATNF @180lifesciences now holds over [-----] ETH signaling a bold pivot into crypto wealth. Check this out to know more https://biotechhealthx.com/biotech-news/180-life-sciences-atnf-acquires-82k-eth-after-425m-raise/ https://biotechhealthx.com/biotech-news/180-life-sciences-atnf-acquires-82k-eth-after-425m-raise/"
X Link 2025-10-26T07:59Z [---] followers, [--] engagements
"$CELZ @creativemedica1's net loss improved to $1.23 million with major upside momentum. Check the full story here. https://biotechhealthx.com/biotech-news/creative-medical-celz-narrows-loss-by-21-and-shares-jump-14/ https://biotechhealthx.com/biotech-news/creative-medical-celz-narrows-loss-by-21-and-shares-jump-14/"
X Link 2025-10-26T08:16Z [---] followers, [--] engagements
"$KYTX @Kyverna_Tx's leading-edge CAR T pipeline targets massive unmet medical markets. Here's what makes it a smart long-term investment. https://biotechhealthx.com/biotech-news/kyverna-kytx-could-become-the-1st-10b-autoimmune-car-t-company/ https://biotechhealthx.com/biotech-news/kyverna-kytx-could-become-the-1st-10b-autoimmune-car-t-company/"
X Link 2025-10-26T08:17Z [---] followers, [---] engagements
"$EUDA New market entry in India positions @EUDAHealth Holdings Limited for exponential revenue growth in [----]. Click here to know more https://biotechhealthx.com/biotech-news/euda-health-euda-launches-strategic-india-partnership/ https://biotechhealthx.com/biotech-news/euda-health-euda-launches-strategic-india-partnership/"
X Link 2025-10-26T08:43Z [---] followers, [--] engagements
"$IMRN @ImmuronLtd boosts R&D funding to expand its oral immunotherapy pipeline and strengthen IMRN stocks biotech outlook in [----]. https://biotechhealthx.com/biotech-news/immuron-imrn-raises-8-5m-for-biotech-expansion/ https://biotechhealthx.com/biotech-news/immuron-imrn-raises-8-5m-for-biotech-expansion/"
X Link 2025-11-06T17:36Z [---] followers, [--] engagements
"$MTSR Two pharma titans @pfizer and @teamnovonordisk fight for control of @MetseraInc's next-gen obesity pipeline in record-setting biotech battle. https://biotechhealthx.com/biotech-info/pfizer-vs-novo-nordisk-the-10b-war-over-metsera-mtsr/ https://biotechhealthx.com/biotech-info/pfizer-vs-novo-nordisk-the-10b-war-over-metsera-mtsr/"
X Link 2025-11-06T17:37Z [---] followers, [---] engagements
"$GKOS Brown Capitals $34.6M sale didnt shake confidence. @GlaukosCorp's glaucoma implants 22% revenue growth and $475M sales forecast fuel optimism. https://biotechhealthx.com/biotech-news/why-glaukos-gkos-could-surge-30-in-2025/ https://biotechhealthx.com/biotech-news/why-glaukos-gkos-could-surge-30-in-2025/"
X Link 2025-11-06T17:39Z [---] followers, [--] engagements
"$INDV @Indivior boosts full-year outlook following strong execution in OUD platform; can INDV double Click here to know more https://biotechhealthx.com/biotech-news/why-indivior-indv-just-raised-2025-revenue-guidance-to-1-18-1-22b/ https://biotechhealthx.com/biotech-news/why-indivior-indv-just-raised-2025-revenue-guidance-to-1-18-1-22b/"
X Link 2025-11-06T18:05Z [---] followers, [--] engagements
"$VIVS VivoSim Labs jumps as the company reports key simulation-model advancement and eyes non-animal biotech market growth. https://biotechhealthx.com/biotech-news/vivosim-labs-vivs-surges-19-8-after-clinical-trial-breakthrough/ https://biotechhealthx.com/biotech-news/vivosim-labs-vivs-surges-19-8-after-clinical-trial-breakthrough/"
X Link 2025-11-06T18:06Z [---] followers, [--] engagements
"$TECX Wall Street turns bullish on Tectonic Therapeutic after strong TX45 heart failure results. Check this article to learn more https://biotechhealthx.com/biotech-news/tectonic-therapeutic-tecx-gets-bullish-boost-analysts-predict-330-rally/ https://biotechhealthx.com/biotech-news/tectonic-therapeutic-tecx-gets-bullish-boost-analysts-predict-330-rally/"
X Link 2025-11-06T18:07Z [---] followers, [---] engagements
"$GH DCF model shows @GuardantHealth trading 61.9% below fair value despite massive [----] rally. Read this article to know more. https://biotechhealthx.com/biotech-news/why-analysts-see-guardant-health-gh-rallying-to-249/ https://biotechhealthx.com/biotech-news/why-analysts-see-guardant-health-gh-rallying-to-249/"
X Link 2025-11-06T18:12Z [---] followers, [--] engagements
"$INVA Innoviva posts revenue of $107.8M and net income of $89.9 million in Q3 [----] marking its strongest quarter ever and a $125M buyback launch. https://biotechhealthx.com/biotech-news/innoviva-inva-surges-after-record-q3-2025-earnings/ https://biotechhealthx.com/biotech-news/innoviva-inva-surges-after-record-q3-2025-earnings/"
X Link 2025-11-08T08:33Z [---] followers, [---] engagements
"$AFJK Aimei Health Technology trades at $11.33 with a 1-year high of $11.49. Could its $69M SPAC war chest fuel a surprise rally https://biotechhealthx.com/biotech-news/can-aimei-health-afjk-defy-weiss-ratings-bearish-call/ https://biotechhealthx.com/biotech-news/can-aimei-health-afjk-defy-weiss-ratings-bearish-call/"
X Link 2025-11-08T08:34Z [---] followers, [--] engagements
"$IOVA Trading at just $2.31 with a fair value of $8.X @IovanceBio offers 71% upside driven by FDA approval growing sales & a massive oncology pipeline. https://biotechhealthx.com/biotech-news/iovance-bio-iova-the-most-undervalued-cancer-stock-in-the-market/ https://biotechhealthx.com/biotech-news/iovance-bio-iova-the-most-undervalued-cancer-stock-in-the-market/"
X Link 2025-11-08T08:35Z [---] followers, [---] engagements
"$TECX Tectonic Therapeutics posts strong Phase 1b results in PH-HFrEF and reports $268.4M in cash giving a solid runway through [----]. https://biotechhealthx.com/biotech-news/tectonic-therapeutics-tecx-surges-on-positive-tx45-trial-data/ https://biotechhealthx.com/biotech-news/tectonic-therapeutics-tecx-surges-on-positive-tx45-trial-data/"
X Link 2025-11-08T08:35Z [---] followers, [---] engagements
"$URGN Phase [--] UTOPIA trial results boost confidence in UGN-103 pushing @UroGenPharma closer to a [----] NDA submission and potential market expansion. https://biotechhealthx.com/biotech-info/urogen-urgns-ugn-103-delivers-77-8-success-rate/ https://biotechhealthx.com/biotech-info/urogen-urgns-ugn-103-delivers-77-8-success-rate/"
X Link 2025-11-08T15:50Z [---] followers, [--] engagements
"$PEN Penumbra jumps after Q3 [----] earnings beat; $355 M revenue and $1.17 EPS spark stronger [----] forecasts. Click here to learn more https://biotechhealthx.com/biotech-news/penumbra-pen-reports-355m-revenue-29-eps-beat/ https://biotechhealthx.com/biotech-news/penumbra-pen-reports-355m-revenue-29-eps-beat/"
X Link 2025-11-08T15:50Z [---] followers, [--] engagements
"$NHTC Natural Health Trends posts Q3 [----] revenue of just $9.5 M down 11% year-over-year as restructuring kicks in. Click here to know more https://biotechhealthx.com/biotech-news/natural-health-trends-nhtc-q3-revenue-falls-11-to-9-5-m/ https://biotechhealthx.com/biotech-news/natural-health-trends-nhtc-q3-revenue-falls-11-to-9-5-m/"
X Link 2025-11-09T06:53Z [---] followers, [--] engagements
"$ACOG @AlphaCognition1 is positioning itself as a leader in neurodegenerative treatment innovation with ZUNVEYL. Read this article to know more. https://biotechhealthx.com/biotech-news/why-alpha-cognition-acog-could-be-the-next-big-alzheimers-breakthrough-stock/ https://biotechhealthx.com/biotech-news/why-alpha-cognition-acog-could-be-the-next-big-alzheimers-breakthrough-stock/"
X Link 2025-11-09T07:41Z [---] followers, [---] engagements
"$CRMD CorMedix Inc. reports record Q3 [----] profit of $108.6M and raises full-year revenue guidance to $410M investors take notice. https://biotechhealthx.com/biotech-news/cormedix-crmd-surges-after-posting-108-6m-net-income-in-q3-2025/ https://biotechhealthx.com/biotech-news/cormedix-crmd-surges-after-posting-108-6m-net-income-in-q3-2025/"
X Link 2025-11-12T17:17Z [---] followers, [---] engagements
"$VKTX Leaders in the obesity treatment space estimate a $100 B market by [----] Viking Therapeutics is positioned to capture major share. https://biotechhealthx.com/biotech-news/why-viking-therapeutics-vktx-could-dominate-the-100b-obesity-drug-market-by-2030/ https://biotechhealthx.com/biotech-news/why-viking-therapeutics-vktx-could-dominate-the-100b-obesity-drug-market-by-2030/"
X Link 2025-11-12T17:18Z [---] followers, [---] engagements
"$ABEO Abeona cuts net loss from $30.3 M to $5.2 M and expands rare-disease network as ZEVASKYN demand surges ahead of launch. https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-slashes-quarterly-loss-by-83/ https://biotechhealthx.com/biotech-news/abeona-therapeutics-abeo-slashes-quarterly-loss-by-83/"
X Link 2025-11-12T17:19Z [---] followers, [--] engagements
"$TRVI Trevi Therapeutics (TRVI) shocks investors with a massive $194.9 million cash and securities balance securing a runway into [----] while advancing Haduvio for chronic cough in IPF and RCC. Learn why analysts expect major upside. https://biotechhealthx.com/biotech-news/trevi-therapeutics-trvi-surges-as-cash-runway-extends-to-2028-after-reporting-194-9m-assets/ https://biotechhealthx.com/biotech-news/trevi-therapeutics-trvi-surges-as-cash-runway-extends-to-2028-after-reporting-194-9m-assets/"
X Link 2025-11-16T07:09Z [---] followers, [---] engagements
"$CDTX Shares of @CidaraThera (NASDAQ:CDTX) doubled to $217.89 after Merck offered a 108.9% premium to buy the company. With the FDA granting breakthrough designation to CD388 and a 6000-patient Phase [--] trial underway this could be the biotech breakout of the decade. https://biotechhealthx.com/biotech-news/cidara-therapeutics-cdtx-skyrockets-108-9-as-merck-acquisition-hits-221-50-per-share/ https://biotechhealthx.com/biotech-news/cidara-therapeutics-cdtx-skyrockets-108-9-as-merck-acquisition-hits-221-50-per-share/"
X Link 2025-11-16T07:09Z [---] followers, [--] engagements
"$MRSN Mersana Therapeutics (MRSN) announces a blockbuster merger worth up to $285M including $25 cash per share and $30.25 in CVRs tied to Emi-Le milestones. Heres why the ADC developer is suddenly a biotech standout. https://biotechhealthx.com/biotech-news/mersana-therapeutics-mrsn-surges-after-285m-acquisition-deal-with-day-one-biopharmaceuticals/ https://biotechhealthx.com/biotech-news/mersana-therapeutics-mrsn-surges-after-285m-acquisition-deal-with-day-one-biopharmaceuticals/"
X Link 2025-11-16T07:10Z [---] followers, [--] engagements
"$KRRO @KorroBio (KRRO) confirmed functional M-AAT protein production in AATD patients in its Phase 1/2a REWRITE trial. With RNA editing validated in humans regulatory breakthroughs and GalNAc programs advancing into [--------] KRRO becomes one of the hottest genetic medicine stocks to watch. https://biotechhealthx.com/biotech-news/korro-bio-krro-surges-after-human-rna-editing-success-in-aatd-trial/ https://biotechhealthx.com/biotech-news/korro-bio-krro-surges-after-human-rna-editing-success-in-aatd-trial/"
X Link 2025-11-16T07:26Z [---] followers, [---] engagements
"$TWST @TwistBioscience ended fiscal [----] with $232.4M in cash and short-term investments despite heavy operating expenses of $327.3M. As the company invests in MRD Express protein solutions and AI discovery tools investors question whether future dilution or debt will be needed to sustain growth. https://biotechhealthx.com/biotech-news/twist-bioscience-twst-cash-position-hits-232-4m-is-it-enough-to-fund-2026-expansion/ https://biotechhealthx.com/biotech-news/twist-bioscience-twst-cash-position-hits-232-4m-is-it-enough-to-fund-2026-expansion/"
X Link 2025-11-16T07:27Z [---] followers, [---] engagements
"$OSCR @OscarHealth (NASDAQ:OSCR) projects strong revenue growth through [----] driven by ACA expansion AI-driven plans and its +Oscar full-stack platform. With an earnings swing from $161.2M to +$245.4M OSCR could be one of the most undervalued tech-enabled insurers today. https://biotechhealthx.com/biotech-news/why-analysts-believe-oscar-health-oscr-could-become-a-12b-plus-digital-insurance-powerhouse/ https://biotechhealthx.com/biotech-news/why-analysts-believe-oscar-health-oscr-could-become-a-12b-plus-digital-insurance-powerhouse/"
X Link 2025-11-16T15:46Z [---] followers, [---] engagements
"$YDES YD Bio Limited (YDES) became a Nasdaq-listed biotech after completing a major merger and securing $13.2M in PIPE financing. With DNA methylation cancer detection for pancreatic and breast cancer and exosome-based eye therapies in development investors are asking whether YDES is positioned for massive growth in [----] and beyond. https://biotechhealthx.com/biotech-news/yd-bio-ydes-surges-after-13-2m-financing/ https://biotechhealthx.com/biotech-news/yd-bio-ydes-surges-after-13-2m-financing/"
X Link 2025-11-16T15:47Z [---] followers, [--] engagements
"$APUS Following its ai Futures Lab expansion and continued progress of Apitox in late-stage development @apimedsai2 appears significantly undervalued relative to its innovative platform. Discover why APUS may offer substantial upside as investors search for the next non-opioid breakthrough. https://biotechhealthx.com/biotech-news/is-apimeds-apus-the-most-undervalued-small-cap-biotech/ https://biotechhealthx.com/biotech-news/is-apimeds-apus-the-most-undervalued-small-cap-biotech/"
X Link 2025-11-16T15:48Z [---] followers, [--] engagements
"$INDP INDP stock gains attention as @indaptus secures $2.3M through its ATM facility completes its Safety Lead-In cohort and posts improving financial trendspositioning the company for a pivotal clinical expansion heading into [----]. https://biotechhealthx.com/biotech-news/why-indaptus-indp-could-be-a-sleeper-biotech-winner-after-2-3m-financing-boost-and-phase-1-progress/ https://biotechhealthx.com/biotech-news/why-indaptus-indp-could-be-a-sleeper-biotech-winner-after-2-3m-financing-boost-and-phase-1-progress/"
X Link 2025-11-18T04:05Z [---] followers, [--] engagements
"$CYPH Cypherpunk Technologies (CYPH) surged 284% in just one week after rebranding from Leap Therapeutics and launching a bold $58.9 million Zcash treasury strategy. Learn why investors believe CYPHs digital-asset pivot could unlock massive upside despite a 37x price-to-book ratio. https://biotechhealthx.com/biotech-news/cypherpunk-technologies-cyph-skyrockets-284-in-one-week-after-58-9m-crypto-pivot/ https://twitter.com/i/web/status/1990632661275324644 https://biotechhealthx.com/biotech-news/cypherpunk-technologies-cyph-skyrockets-284-in-one-week-after-58-9m-crypto-pivot/"
X Link 2025-11-18T04:06Z [---] followers, [---] engagements
"$RYTM Rhythm Pharmaceuticals Inc. (RYTM) faces a three-month FDA review extension for IMCIVREE in acquired hypothalamic obesity moving the PDUFA date to March [--] [----]. With Q3 revenue rising to $51.3M from $33.25M YoY investors now wonder whether the delay signals a massive upside opportunity for this rare-disease leader. https://biotechhealthx.com/biotech-news/rhythm-pharma-rytm-surges-as-fda-extends-review-for-imcivree/ https://biotechhealthx.com/biotech-news/rhythm-pharma-rytm-surges-as-fda-extends-review-for-imcivree/"
X Link 2025-11-18T04:35Z [---] followers, [---] engagements
"$BDTX Black Diamond Therapeutics (BDTX) soared 115.9% year-to-date and hit a new 52-week high at $4.65. With four straight earnings beats and a Zacks Rank #2 Buy rating analysts project $0.46 EPS on $70M revenue. See why BDTX may still be massively undervalued. https://biotechhealthx.com/biotech-news/black-diamond-therapeutics-bdtx-surges-115-9-ytd/ https://biotechhealthx.com/biotech-news/black-diamond-therapeutics-bdtx-surges-115-9-ytd/"
X Link 2025-11-18T04:36Z [---] followers, [---] engagements
"$AVTX Avalo Therapeutics Inc. (AVTX) received a reaffirmed $48 price target from Piper Sandler implying a stunning 167.86% upside. With AVTX-009 advancing in Phase [--] hidradenitis suppurativa trials and new leadership strengthening execution analysts say this immunology stock may be one of biotechs biggest long-term winners. https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-set-for-167-86-surge-piper-sandler-reaffirms-massive-48-price-target/ https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtx-set-for-167-86-surge-piper-sandler-reaffirms-massive-48-price-target/"
X Link 2025-11-18T04:37Z [---] followers, [---] engagements
"$FULC FULC stock gains momentum as pociredir demonstrates dose-dependent HbF induction and no treatment-related SAEs. With $200.6M cash and multiple IND programs planned Fulcrum Therapeutics (NASDAQ: FULC) positions itself as a top genetic-disease biotech to watch in [----]. https://biotechhealthx.com/biotech-news/is-fulcrum-therapeutics-fulc-the-next-rare-disease-winner-new-data-says-yes/ https://biotechhealthx.com/biotech-news/is-fulcrum-therapeutics-fulc-the-next-rare-disease-winner-new-data-says-yes/"
X Link 2025-11-18T04:37Z [---] followers, [---] engagements
"$OLMA Olema Pharmaceuticals (NASDAQ:OLMA) gained massive investor attention after Roche announced positive Phase [--] results for giredestrant validating the same drug class as Olemas lead therapy palazestrant. Learn why this breakthrough could dramatically increase OLMAs probability of trial success and long-term valuation"
X Link 2025-11-19T05:47Z [---] followers, [--] engagements
"$KZIA Kazia Therapeutics (NASDAQ:KZIA) now faces imminent delisting after failing to regain NASDAQ compliance by Nov. [--] [----]. With a market cap of only $10.47M declining revenues negative equity and strong sell technical signals KZIA investors are bracing for a possible suspension. https://biotechhealthx.com/biotech-news/kazia-therapeutics-kzia-faces-nasdaq-delisting-after-missing-compliance-deadline-is-this-the-end/ https://biotechhealthx.com/biotech-news/kazia-therapeutics-kzia-faces-nasdaq-delisting-after-missing-compliance-deadline-is-this-the-end/"
X Link 2025-11-19T05:49Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing